Importance of COMT in the regulation of prefrontal dopamine by Käenmäki, Mikko
Division of Pharmacology and Toxicology 
Faculty of Pharmacy 
University of Helsinki 
Finland 
and 
Department of Pharmacology 
University of Oxford 
United Kingdom 
Importance of COMT in the regulation of 
prefrontal dopamine 
MIKKO KÄENMÄKI 
ACADEMIC DISSERTATION 
To be presented, with the permission of the Faculty of Pharmacy at the 
University of Helsinki, for public examination at Viikki Biocentre,  
Auditorium 1041, on February 17th 2012 at 12 noon. 
Helsinki 2012
 Supervised by 
 
Professor Pekka T. Männistö, MD, PhD 
Division of Pharmacology and Toxicology 
Faculty of Pharmacy 
University of Helsinki 
Finland 
Reviewed by 
 
Professor Seppo Soinila, MD, PhD 
Department of Neurology 
Turku University Central Hospital 
Finland 
 
Docent Erkki Nissinen, PhD 
Orion Oyj 
Finland 
Examined by 
 
Professor Seppo Kaakkola, MD, PhD 
Department of Neurology 
Helsinki University Central Hospital 
Finland 
ISBN 978-952-10-7613-8 (paperback) 
ISBN 978-952-10-7614-5 (pdf) 
ISNN 1799-7372 
Yliopistopaino, University Press 
Helsinki, Finland 2012 
 To Kasper and Amos 
 
 
 
 
 
 
 
 ABSTRACT 
ABBREVIATIONS 
LIST OF ORIGINAL PUBLICATIONS 
1  INTRODUCTION .................................................................................................... 1 
2  REVIEW OF LITERATURE.................................................................................. 3 
2.1 Anatomy and function of the prefrontal cortex.................................................... 3 
2.2 Anatomy and function of the medial prefrontal cortex ........................................ 5 
2.3 Medial prefrontal cortical neural circuits ............................................................. 6 
2.3.1 Cerebral cortex ............................................................................................. 6 
2.3.2 Thalamus....................................................................................................... 6 
2.3.3 Hypothalamus ............................................................................................... 7 
2.3.4 Basal ganglia ................................................................................................ 8 
2.3.5 Brainstem ...................................................................................................... 8 
2.3.6 Basal forebrain ............................................................................................. 9 
2.3.7 Limbic structures ........................................................................................ 10 
2.4 Neurotransmitters and modulation of neuronal activity..................................... 11 
2.4.1 Dopamine & DAT ....................................................................................... 11 
2.4.2 Noradrenaline & NET ................................................................................ 14 
2.4.3 5-hydroxytryptamine ................................................................................... 15 
2.4.4 Histamine .................................................................................................... 16 
2.4.5 Glutamate.................................................................................................... 17 
2.4.6 Acetylcholine............................................................................................... 18 
2.4.7 GABA .......................................................................................................... 19 
2.5 COMT and the prefrontal cortex........................................................................ 20 
3  AIMS OF THE STUDY ......................................................................................... 22 
4  MATERIALS AND MAIN METHODS............................................................... 23 
4.1 Animals and genotyping .................................................................................... 23 
4.2 Drugs and treatments.......................................................................................... 24 
4.3 COMT activity assay.......................................................................................... 24 
4.4 Assay of monoamines in plasma and tissue samples ......................................... 25 
4.4.1 Methodological considerations................................................................... 25 
4.5 Immunoblotting.................................................................................................. 26 
4.6 Immunohistochemistry....................................................................................... 26 
4.7 In vivo microdialysis .......................................................................................... 26 
4.7.1 Stereotactic surgery .................................................................................... 26 
4.7.2 Conventional microdialysis ........................................................................ 27 
4.7.3 No-net-flux microdialysis............................................................................ 27 
4.7.4 Methodological considerations................................................................... 27 
4.8 Data analysis and statistics................................................................................. 27 
 5  RESULTS ................................................................................................................ 29 
5.1 COMT activity in S-COMT deficient mice (Study I) ........................................ 29 
5.2 Pharmacokinetics of oral carbidopa/L-dopa in COMT-KO and S-COMT 
deficient mice (Study I) ..................................................................................... 30 
5.2.1 Peripheral tissues ....................................................................................... 30 
5.2.2 Brain tissues................................................................................................ 31 
5.3 Western blotting and COMT protein distribution in S-COMT deficient  
mice (Study I) .................................................................................................... 31 
5.4 Extracellular striatal, accumbal and prefrontal dopamine and metabolite  
levels in S-COMT deficient mice after cabidopa/L-dopa administration  
(Study II)............................................................................................................ 32 
5.5 Extracellular striatal, accumbal and prefrontal dopamine and metabolite 
levels in COMT-KO mice after carbidopa/L-dopa administration  
(unpublished) ..................................................................................................... 32 
5.6 Baseline extracellular striatal, accumbal and prefrontal dopamine levels 
in COMT-KO mice (Study III).......................................................................... 35 
5.7 Presence of DAT and NET in striatum and prefrontal cortex of COMT-KO 
mice (Study III).................................................................................................. 36 
5.8 Extracellular striatal, accumbal and prefrontal dopamine and metabolite 
levels in COMT-KO mice after DAT, NET and MAO inhibition 
(Study III) .......................................................................................................... 36 
5.9 Striatal and accumbal extracellular dopamine and metabolite levels after  
tolcapone and THC administration (Study IV).................................................. 37 
6  DISCUSSION .......................................................................................................... 39 
6.1 Distinguishing the role of COMT isoforms in general – Impact on 
enzyme activity and pharmacokinetics of oral L-dopa...................................... 39 
6.2 Distinguishing the role of COMT isoforms in the brain – Impact on 
extracellular dopamine levels in the striatum, nucleus accumbens  
and mPFC .......................................................................................................... 40 
6.3 Role of COMT, DAT, NET and MAO on prefrontal dopamine 
metabolism in mice............................................................................................ 42 
6.4 Effects of simultaneous COMT inhibition and THC on extracellular 
dopamine levels in the stratum and nucleus accumbens ................................... 44 
7  CONCLUSIONS ..................................................................................................... 46 
8  ACKNOWLEDGEMENTS ................................................................................... 47 
9  REFERENCES ....................................................................................................... 49 
APPENDIX: ORIGINAL PUBLICATIONS I-IV 
 
 ABSTRACT 
The prefrontal cortex (PFC), located in the anterior region of the frontal lobe, is 
considered to have several key roles in higher cognitive and executive functions. In 
general, the PFC can be seen as a coordinator of thought and action allowing subjects 
to behave in a goal-directed manner. Due to its anatomical connections with a variety 
of cortical and subcortical structures, several neurotransmitters, including dopamine, 
are involved in the regulation of PFC activity. In general, the majority of released 
dopamine is cleared by the dopamine transporter (DAT). In the PFC however, the 
number of presynaptic DAT is diminished, emphasizing the relative importance of 
catechol-O-methyltransferase (COMT) in dopamine metabolism. As a result, the role 
of COMT in the etiology of psychotic disorders is under constant debate. 
 The present study investigated the role of COMT in prefrontal cortical dopamine 
metabolism by different neurochemical methods in COMT knockout (COMT-KO) 
mice. Pharmacological tools to inhibit other dopamine clearing mechanisms were also 
used for a more comprehensive and collective picture.  In addition, this study 
investigated how a lack of the soluble (S-) COMT isoform affects the total COMT 
activity as well as the pharmacokinetics of orally administered L-dopa using mutant 
mice expressing only the membrane-bound (MB-) COMT isoform. Also the role of 
COMT in striatal and accumbal dopamine turnover during Δ9-tetrahydrocannabinol 
(THC) challenge was studied. 
 We found markedly increased basal dopamine concentrations in the PFC, but not 
the striatum or nucleus accumbens (NAcc), of mice lacking COMT. Pharmacological 
inhibition of the noradrenaline transporter (NET) and monoamine oxidase (MAO) 
elevated prefrontal cortical dopamine levels several-fold, whereas inhibition of DAT 
did not. The lack of COMT doubled the dopamine raising effects of NET and MAO 
inhibition. No compensatory expression of either DAT or NET was found in the 
COMT-KO mice. The lack of S-COMT decreased the total COMT activity by 50-70 
% and modified dopamine transmission and the pharmacokinetics of exogenous L-
dopa in a sex and tissue specific manner. Finally, we found that subsequent tolcapone 
and THC increased dopamine levels in the NAcc, but not in the striatum. 
Conclusively, this study presents neurochemical evidence for the important role of 
COMT in the PFC and shows that COMT is responsible for about half of prefrontal 
cortical dopamine metabolism. This study also highlights the previously 
underestimated proportional role of MB-COMT and supports the clinical evidence of a 
gene x environment interaction between COMT and cannabis. 
 ABBREVIATIONS 
3-OMD     3-O-methyldopa 
5-HT      5-Hydroxytryptamine 
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AID      Dorsal agranular insular cortex 
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ANOVA     Analysis of variance 
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AUC      Area under the curve 
CB1       Cannabinoid receptor type 1  
Cg1      Cingulate cortex area 1 
Cg2      Cingulate cortex area 2 
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CPu      Caudate putamen 
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DAT      Dopamine transporter 
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1   INTRODUCTION 
In the mid 19th century, the skull of a railroad worker named Phineas Gage was 
accidentally pierced by an iron bar destroying most of the left frontal lobe and causing 
severe injury to his left and right prefrontal cortex (PFC) (Malenfant et al., 2011). The 
post injury deterioration occurred mainly as restlessness, deliriousness, an infection 
and impaired vision in his left eye, but he had normal awareness and could walk and 
speak normally (Haas, 2001). Though it had appeared that Mr. Gage was relatively 
uninjured after the severe accident, the incident caused a previously unreported 
distinct behavioural syndrome with permanent personality changes. According to 
reports, the impairment had made him irreverent, grossly profane and showing little 
respect for others. He was also unable to proceed with any plans since the accident left 
him impatient, obstinate and fitful. More evidence of frontal lobe impairments was 
gained, when Gottlieb Burckhardt and his follower Egas Moniz started performing 
pioneering cerebral cortical excisions to relieve mental illness (Stone, 2001). At the 
time, the lack of effective medication in the field of psychiatry led to the development 
and introduction of psychosurgery. The theories of these two pioneers were evolved 
from late 19th century discoveries of cerebral cortical localization, and they founded 
on the premise of localized physical basis for severe mental disorders. The pacifying 
effect of frontal lobectomies disrupting cortical areas in experimental animals 
suggested that affective behaviour is cortically located. Moniz, the father of "modern" 
psychosurgery, believed that the mental symptoms perceived by the violent or 
antisocial psychotic patients where in fact a result of deviant prefrontal circuits, and 
the partial ablation of these circuits would remove these symptoms. 
Dopamine is a neurotransmitter linked to a variety of functions affecting performance 
in cognitive tasks, including motivation, reward, affect and movement (Goldman-
Rakic et al., 2000). The presence of dopamine in the PFC and the mesocortical 
pathway was discovered by Thierry and co-workers in the early 1970's (Berger et al., 
1974; Thierry et al., 1973), whose research paved the way for understanding the 
neuromodulatory role of prefrontal cortical dopamine. Now it is generally accepted 
that dysregulation, or functional impairment of dopaminergic neurotransmission in the 
PFC is associated with the cognitive deficits in a variety of diseases, including 
schizophrenia (Knable and Weinberger, 1997), depression (Gorwood, 2008) and even 
in some features of Parkinson's disease (Gotham et al., 1988). 
Catechol-O-methyltransferase (COMT) is an intracellular enzyme that O-methylates 
L-dopa, catecholamine transmitters such as dopamine, catecholestrogens and a variety 
of xenobiotic compounds (Axelrod, 1966; Guldberg and Marsden, 1975). COMT is 
widely distributed both in central and peripheral tissues, with high abundance seen 
peripherally in the liver and kidney and centrally in the hippocampus and the PFC 
(Matsumoto et al., 2003; Myöhänen et al., 2010). A single COMT gene contains two 
distinct promoters and codes for two separate enzymes: soluble (S-) COMT and 
membrane bound (MB-) COMT (Männistö and Kaakkola, 1999). S-COMT is more 
abundant in peripheral tissues while MB-COMT prevails in the brain, particularly in 
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humans. The two isoforms of COMT have been proposed to have at least partially 
distinct roles: MB-COMT, a high-affinity isoform of COMT, is supposed to be 
primarily responsible for the termination of dopaminergic and noradrenergic synaptic 
neurotransmission. S-COMT on the other hand, is a high capacity isoform being 
mainly responsible for the elimination of biologically active or toxic, particularly 
exogenous, catechols and some hydroxylated metabolites. COMT acts also as an 
enzymatic, detoxifying barrier between the blood and other tissues, shielding from the 
harmful effects of hydroxylated xenobiotics (Kaakkola et al., 1994; Männistö et al., 
1992b). In addition, COMT may be responsible for modulating some excretory 
functions in the kidney and the intestinal tract by regulating the dopaminergic tone 
(Eklof et al., 1997; Hansell et al., 1998; Kaakkola et al., 1994). The same may be true 
in the brain: COMT activity regulates the amounts of active dopamine, particularly in 
frontal cortical areas, and may therefore be associated with mood and other mental 
processes (Tunbridge et al., 2006; Yavich et al., 2007). 
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2   REVIEW OF LITERATURE 
2.1  Anatomy and function of the prefrontal cortex 
The PFC, first described as the cortical region with reciprocal connections with the 
mediodorsal nucleus of thalamus (MD) (Rose and Woolsey, 1948), has an essential 
role in a variety of higher cognitive and executive processes that involve motivation, 
emotion, learning and memory (Dalley et al., 2004; Miller and Cohen, 2001; Ongur 
and Price, 2000; Robbins, 2000). However, since this first, single criteria definition of 
the PFC, it has become clear that due to the sheer complexity of the area, other 
functional and anatomical characteristics are also needed for identification. Though 
there are apparent anatomical differences between the primate and rodent cortices, the 
general consensus is, in spite of cross-species variation in the amount of granular and 
agranular cortex, that both orders possess a brain structure that can be named as the 
PFC (Uylings and van Eden, 1990; Uylings et al., 2003). The following review will 
focus on rodents, but will not distinguish between the species-specific anatomical and 
sometimes functional differences, and will concentrate on the PFC as an area of the 
brain in general. The criteria for closer inspection of homologies between cortical 
areas in different species were outlined by Uylings et al. (2003). 
The PFC in rats can be divided into three topologically and functionally different 
regions (Fig. 2.1). Anatomically, these regions can be distinguished either based on 
their differential innervations by the MD, their cytoarchitectonic features, their input 
of dopaminergic fibers from the ventral mesencephalon or a combination of these 
criteria (Heidbreder and Groenewegen, 2003). The first of these is the lateral part of 
the PFC, termed either lateral or sulcal PFC or the agranular insular cortex, located in 
the anterior part of the rhinal sulcus. The second is the medial part of the PFC (medial 
PFC, mPFC) located on the medial wall of the hemisphere, anterior and dorsal to the 
genu of corpus callosum. The third region is a ventral part of the PFC, also termed the 
orbital PFC, which lies in part dorsal to the caudal end of the olfactory bulb in the 
dorsal bank of the rhinal sulcus. (Groenewegen, 1988; Krettek and Price, 1977; Sarter 
and Markowitsch, 1983; Sarter and Markowitsch, 1984; Steketee, 2003). In primates, 
apart from the ones mentioned above, one additional region with limited accounts of 
function has been named (Ramnani and Owen, 2004): the anterior prefrontal cortex 
(aPFC) is located in the most anterior part of the frontal lobe and comprises a 
significantly larger proportion of the cortex in humans than in other species 
(Semendeferi et al., 2001). 
One of the most studied aspects of prefrontal cortical function is its role in working 
memory, thought to arise from networks of pyramidal cells with shared properties. 
This role can be summarized as the prefrontal cortices ability to manipulate items in 
short-term memory to plan, organize and manipulate information required to generate 
future thought of action, thus allowing planning of actions based on memory (Seamans 
and Yang, 2004). Optimal function of the PFC allows therefore the regulation of 
attention, the inhibition of inappropriate motor responses and planning for the future. 
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Figure 2.1. Saggital (A) and coronal (B) 
sections of the rat prefrontal cortex 
(PFC). The saggital view is 0.9 mm 
lateral from the midline and the coronal 
section is depicted approximately 3.5 mm 
anterior of bregma. The three major 
regions (medial, ventral and lateral) of 
the PFC are represented in the coronal 
section as different shadings.  AIV, 
ventral agranular insular cortex; AID, 
dorsal agranular insular cortex;  Cg1 and 
2, cingulate cortex areas 1 and 2; IL, 
infralimbic cortex; LO, lateral orbital 
cortex; M1, primary motor cortex; MO, 
medial orbital cortex; PL, prelimbic 
cortex; PrC, precentral cortex; VLO, 
ventrolateral cortex; VO, ventral orbital 
cortex. Modified from Dalley et al. 
(2004). 
 
The functional divergence between the prefrontal cortical regions is seen as the dorsal-
lateral sector's involvement in working memory processes, planning and decision 
making, and the ventral-medial sector's involvement in reward oriented behaviours, 
reversal learning, emotion and the organization of personality as well as appropriate 
social behaviour. Due to its connectional anatomy with inputs from cortical areas 
associated with most sensory systems, the orbital PFC is thought to be involved in the 
integration of sensory information, particularly in the assessment of food, and to guide 
response and decision making (Price, 2007; Rolls, 2005). The aPFC, also due to its 
connectional and cellular anatomy, has been suggested as a coordinator of information 
processing and transfer between multiple cognitive operations (Ramnani and Owen, 
2004). 
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2.2  Anatomy and function of the medial prefrontal cortex 
In anatomical terms, the mPFC can be sub-divided further into a dorsal component 
encompassing the medial precentral, dorsal anterior cingulate and dorsal prelimbic 
areas, and a ventral component encompassing the ventral prelimbic, infralimbic and 
medial orbital areas with differences in neurotransmitter levels, function and 
projection patterns (Fig. 2.2; for projection patterns see section 2.3) (Berendse et al., 
1992; Heidbreder and Groenewegen, 2003; Ongur and Price, 2000; Steketee, 2003). 
 
Figure 2.2. Coronal sections between 0.2 and 4.7 mm anterior of bregma depicting different areas 
and the extension of the medial prefrontal cortex in rats.  Cg1 and 2, cingulate cortex areas 1 and 2; 
IL, infralimbic cortex; MO, medial orbital cortex; PL, prelimbic cortex; PrC, precentral cortex. 
Modified from Resstel & Corrêa (2006). 
With regards to topographical differences in function and neurotransmitter levels, the 
dorsal part of the mPFC is particularly involved in the temporal shifting of behavioural 
sequences and motor behaviours, whereas the ventral sector, displaying higher 
dopamine levels than dorsal areas, has been associated with emotional, cognitive and 
memory processes (Hedou et al., 1999; Hedou et al., 2001; Heidbreder and 
Groenewegen, 2003). Due to its connections with autonomic centres, the ventral area 
is also responsible for the integration of internal physiological states with 
environmental cues for the guidance of behaviour. 
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2.3  Medial prefrontal cortical neural circuitry 
Similar to the cytoarchitectonic dissociation of the mPFC into a dorsal and ventral 
compartment, these regions can also be identified by their distinct topographical 
differences in connectivity patterns. Generally, the projections to the brainstem 
monoaminergic cell groups and different limbic structures, like the hippocampus and 
amygdala, are more extensive and stronger in ventral than dorsal areas (Jay and Witter, 
1991; Van Eden and Buijs, 2000). The dorsal areas, on the other hand, project 
primarily to areas such as the sensimotor regions of the cerebral cortex and the brain 
stem, the core of the nucleus accumbens (NAcc) and the medial caudate putamen 
(Heidbreder and Groenewegen, 2003). The brain structures that connect with the 
mPFC are summarized in Table 2.1. 
Table 2.1. Brain structures that connect with the medial prefrontal cortex. 
 
Cerebral cortex Brainstem 
Thalamus Basal forebrain 
Hypothalamus Limbic structures 
Basal ganglia  
 
2.3.1  Cerebral cortex 
The majority of axons in the PFC are afferents from other cortical areas such as 
premotor, somatosensory, auditory, visual, olfactory, gustatory and limbic cortices 
(Van Eden et al., 1992). The majority of these sensory inputs are located in the ventral 
areas of the PFC, but some connect with the mPFC as well. Here, the dorsal areas 
appear to have stronger connections to sensory and motor cortical cortices, whereas 
the ventral areas are mainly connected to limbic and higher association cortices 
(Heidbreder and Groenewegen, 2003). In addition, the mPFC contains also mainly 
GABAergic fast spiking and non-fast spiking corticocortical interconnections, which 
constitute approximately 15 % of all neurons (Beaulieu, 1993; Gabbott et al., 1997; 
Retaux et al., 1993). These interconnections are mainly seen as separate internal dorsal 
and ventral projections with less dorsoventral communication (Heidbreder and 
Groenewegen, 2003). 
2.3.2  Thalamus 
The reciprocal glutamatergic connections between the mPFC and different thalamic 
nuclei have been studied extensively (Fig. 2.3) (Ferron et al., 1984; Groenewegen, 
1988; Hurley et al., 1991; Ray and Price, 1992; Vertes, 2002). In general, the 
  7 
thalamocortical connections are important for both differentiation and specialization, 
and are therefore often used to define cerebral cortical areas. With regards to the 
topographical organization, a ventral to dorsal gradient in the mPFC connects to a 
medial to lateral gradient in the dorsal thalamus, whereas strong projections with less 
cortical topography from all mPFC areas reach the ventral thalamus. The reciprocal 
connections to the MD, originally viewed as the PFC defining nucleus as described 
earlier, project from both dorsal and ventral areas of the mPFC (Conde et al., 1990; 
Groenewegen, 1988).  Other nuclei reaching the mPFC include the intralaminar and 
midline nuclei. 
 
Figure 2.3. Depictive illustration of neuronal projections from the rat medial prefrontal cortex 
(mPFC) to the thalamus and hypothalamus as well as indicative neurotransmitters. Glu, glutamate; 
His, histamine. Modified from Paxinos and Watson (1998). 
2.3.3  Hypothalamus 
The mPFC has an important role in influencing behavioural and autonomic functions, 
from feeding and drinking to sexual behaviour, through glutamatergic projections to 
the hypothalamus. These projections arise predominantly from ventrally located 
cortical areas and carry a clear topography from different areas of the mPFC to 
specific regions in the hypothalamus (Fig. 2.3) (Floyd et al., 2001). Histaminergic 
connections running from the tuberomammillary hypothalamic region to the mPFC 
have also been discovered (Wouterlood et al., 1987). 
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2.3.4  Basal ganglia 
From the dorsal part of the mPFC, excitatory projections to the basal ganglia include 
glutamatergic efferents from the medial precentral area to the central part of the 
caudate putamen, from the anterior cingulate cortex to the NAcc core and the medial 
parts of caudate putamen as well as from the dorsal prelimbic cortex to the medial 
caudate putamen bordering the NAcc core (Fig. 2.4) (Cheatwood et al., 2003; Ding et 
al., 2001). The ventral parts on the other hand, include glutamatergic efferents from 
the ventral prelimbic area to the ventromedial caudate putamen, the NAcc core and the 
dorsal-medial parts of NAcc shell and the medial olfactory tubercle. Both the 
infralimbic and medial orbital areas are connected with the medial shell and parts of 
the medial NAcc core (Berendse et al., 1992; Ding et al., 2001; Donoghue and 
Herkenham, 1986; Hurley et al., 1991). Apart from these, the subthalamic nucleus 
(STN) shares reciprocal direct and indirect connections with the prelimbic and medial 
orbital areas, which in addition to the prefrontal cortical connections with the striatum 
play a critical role in the control of movement (Degos et al., 2008; Maurice et al., 
1998; Montaron et al., 1996). 
On the other hand, as a part of the mesocortical pathway, one function of the PFC is to 
regulate the release of dopamine and acetylcholine as well as to integrate sensory and 
limbic information in the NAcc. These actions are mediated directly through efferent 
projections or indirectly via thalamus, hippocampus, amygdala and the ventral 
tegmental area (VTA) (Del Arco and Mora, 2008; Del Arco and Mora, 2009; Gabbott 
et al., 2005; Tzschentke and Schmidt, 2000). The regulation of NAcc activity is 
manifested also through direct excitatory inputs to GABA projecting neurons in the 
mesoaccumbens (Carr and Sesack, 2000b). 
2.3.5  Brainstem 
The major direct dopaminergic input in the mPFC originates from the VTA as a part of 
the mesocortical pathway (Fig. 2.5), with the densest innervation occurring within the 
infralimbic and prelimbic regions (Deutch, 1993; Steketee, 2003; Thierry et al., 1973). 
These projections between the VTA and the mPFC differ through a dorsoventral 
inverted topography. That is, the dorsally located neurons in the VTA project to the 
ventral parts of the mPFC and the more ventrally located neurons innervate the dorsal 
mPFC. Furthermore, the connections between the mPFC and the mesencephalic 
dopaminergic cell groups have a bilaminar distribution, where the substantia nigra pars 
compacta (SNpc) is predominantly responsible for innervating more dorsal and the 
VTA is responsible for innervating more ventral areas of the mPFC (Deutch, 1993). 
The VTA is also responsible for GABAergic innervation of the mPFC (Carr and 
Sesack, 2000a; Yokofujita et al., 2008). Projections running from the mPFC to the 
VTA consist of direct glutamatergic efferents forming synapses with both 
dopaminergic and non-dopaminergic neurons (Carr and Sesack, 1999; Carr and 
Sesack, 2000b; Hurley et al., 1991; Sesack and Pickel, 1992; Taber et al., 1995). 
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Figure 2.4. Depictive illustration of neuronal projections from the rat medial prefrontal cortex 
(mPFC) to selected basal ganglia as well as indicative neurotransmitters. CPu, caudate putamen; 
Glu, glutamate; NAcc, nucleus accumbens. Modified from Paxinos and Watson (1998). 
In addition to the reciprocal projections from the VTA, the mPFC receives 
serotonergic and noradrenergic inputs from two brain stem nuclei, the raphe nuclei and 
locus coeruleus respectively (Fig. 2.5) (Arnsten and Goldman-Rakic, 1984; Chiba et 
al., 2001; Porrino and Goldman-Rakic, 1982; Takagishi and Chiba, 1991). Also 
cholinergic inputs, originating from cell groups in the dorsolateral tegmentum, 
innervate the mPFC (Satoh and Fibiger, 1986). The excitatory efferents that project 
back from the mPFC to both these cholinergic and monoaminergic cell groups 
originate predominantly from the ventral areas of the mPFC. 
2.3.6  Basal forebrain 
Apart from its cholinergic connections with the hippocampus and amygdala, the basal 
forebrain also provides cholinergic innervation of the entire neocortex, including the 
mPFC. The mPFC is however the only cortical area with direct, topographically 
organized glutamatergic projections back to these nuclei (Fig. 2.5) (Gaykema et al., 
1991; Heidbreder and Groenewegen, 2003; Uylings et al., 2003). The dorsoventral 
organization of neurons can largely be seen as dense connectivity of the ventral areas 
to the septum and medial areas of the basal forebrain, while the dorsal areas connect 
more densely to the horizontal limb of the diagonal band of Broca. 
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Figure 2.5. Depictive illustration of neuronal projections from the rat medial prefrontal cortex 
(mPFC) to the brainstem, basal forebrain and limbic structures as well as indicative 
neurotransmitters. 5-HT, 5-hydroxytryptamine; Ach, acetylcholine; DA, dopamine; GABA, γ-
aminobutyric acid; Glu, glutamate; NA, noradrenaline; VTA, ventral tegmental area. Modified from 
Paxinos and Watson (1998). 
2.3.7  Limbic structures 
The hippocampus and amygdala are connected predominantly to ventral areas of the 
mPFC (Carr and Sesack, 1996; Hurley et al., 1991; Jay and Witter, 1991; Mcdonald et 
al., 1996). These glutamatergic connections are reciprocal with regards to the 
amygdala, whereas the projections between the hippocampus and mPFC are virtually 
unidirectional, running predominantly from the hippocampus to the mPFC (Fig. 2.5). 
In addition to the direct interaction, there is an indirect modulation of hippocampal and 
amygdal activity via the dopaminergic and cholinergic efferents from the VTA and the 
basal forebrain, respectively (Carlsen et al., 1985; Gasbarri et al., 1994; Gaykema et 
al., 1990; Sesack and Pickel, 1990). It is noteworthy that although there are only few 
directly connecting fibers running from the mPFC to the hippocampus (Hurley et al., 
1991; Sesack et al., 1989), reciprocal interactions between the hippocampus and other 
areas of the PFC have been described (Groenewegen and Uylings, 2000; Murray and 
Wise, 2010).  
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2.4  Neurotransmitters and modulation of neuronal activity 
Several neurotransmitters and neurochemical modulators contribute to changes in 
prefrontal cortical function. The firing patterns of neurons are tuned by sensitive 
GABAergic inputs and modulated by e.g. catecholamines. This complex system of 
interacting inhibitory and excitatory transmitters in ascending, descending and local 
pathways forms the basis of our capacity to adapt to changing environments. The 
following chapters will review the impact of selected transmitters on the function and 
activity of the mPFC.  
2.4.1  Dopamine & DAT 
Impairment of dopaminergic neurotransmission has been linked to clinical conditions 
such as schizophrenia and Parkinson’s disease. In Parkinson’s disease, the 
degeneration of dopaminergic cell groups in SNpc leads to reduced neuronal activity 
especially within the nigrostriatal pathway, and consequently to a marked loss of 
striatal dopamine (Obeso et al., 2008). Dopaminergic dysfunction is also a core 
component in the etiology of schizophrenia. On the contrary to Parkinson’s disease, 
where dopaminergic transmission is low, schizophrenia is according to the classical 
dopamine hypothesis of schizophrenia caused by an exaggerated dopaminergic 
function in the central nervous system (CNS) (Murray et al., 2008). 
The neuronal activity in the mPFC is modulated by dopamine via two families of 
receptors classified based on their stimulation or inhibition of adenylate cyclase (AC) 
activity (Jackson and Westlind-Danielsson, 1994). The D1-like dopamine receptor 
family (i.e. D1 and D5 receptors) stimulates and the D2-like dopamine receptor family 
(i.e. D2, D3 and D4 receptors) respectively inhibits AC. In addition to its inhibiting 
effect on AC, the D2-like receptors open K+-channels and block voltage activated 
Ca++-channels. All dopamine receptors are G-protein-coupled receptors typically 
consisting of seven transmembrane domains. Unlike classical fast ionotropic receptors, 
the G-protein-coupled receptors are primarily slow metabotropic receptors that 
modulate other receptors and/or ion channels (Seamans and Yang, 2004).  
D1 receptors are the most abundant dopamine receptors in the CNS, with the highest 
levels of expression in the projection areas of midbrain dopamine neurons. The 
importance of D1 receptors in the PFC has been shown both as significantly greater 
distribution of mRNA and a greater amount of receptor binding sites compared with 
other dopamine receptor subtypes (Farde et al., 1987; Gaspar et al., 1995). Both D1 
and D2 receptors are located primarily on intrinsic pyramidal glutamatergic neurons 
and non-pyramidal GABAergic interneurons that synapse on pyramidal neurons 
mainly in layer V of the mPFC (al-Tikriti et al., 1992; Cowan et al., 1994; Gaspar et 
al., 1995). This is also where the majority of D1 and D2 receptor mRNA is found. 
Comparatively, the D2 receptor shows higher affinity to dopamine than the D1 receptor 
(Creese et al., 1983). Thus, it has been suggested that a high amplitude burst firing of 
dopamine neurons (i.e. high concentration phasic dopamine release) activates D1 
receptors and, in contrast, that a basal dopamine transmission, resulting from single 
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spike firing driven by an intrinsic pacemaker potential (i.e. low concentration tonic 
dopamine release) activates D2 receptors (Grace, 1991). Based on their results, Vincent 
et al. (1995) suggested a partial spatial segregation between D1 and D2 receptors, 
where D1 receptors are located preferentially on non-pyramidal neurons and D2 
receptors are located on both pyramidal and non-pyramidal neurons. Co-localization 
on the same non-pyramidal neurons was seen in 25 % of the cases. D4 receptors are 
also located both on pyramidal and non-pyramidal neurons (Mrzljak et al., 1996; 
Wedzony et al., 2000), whereas D3 and D5 receptor mRNA occurs only at low levels in 
the PFC of rats (Laurier et al., 1994; Sokoloff et al., 1990). In addition, dopaminergic 
autoreceptors, coupled to regulation of the release but not the synthesis of dopamine, 
have also been discovered on prefrontal terminals that arise from the VTA (Wolf and 
Roth, 1987). 
Dopaminergic modulation of the mPFC occurs at least through two different 
mechanisms: firstly, through stimulation of GABAergic interneurons increasing 
GABA release in turn inhibiting pyramidal neurons (Grobin and Deutch, 1998; Penit-
Soria et al., 1987) and secondly, through a direct inhibitory effect on the recurrent 
collaterals of pyramidal neurons (Sesack and Bunney, 1989; Thierry et al., 1992). 
Though it may seem that dopamine exclusively inhibits the glutamatergic output of the 
mPFC, recent studies suggest a more modulatory role for dopamine based on several 
other inputs received by these neurons, such as GABAergic inhibitory tone and 
membrane voltage state (Gulledge and Jaffe, 2001; Lavin and Grace, 2001; Tseng and 
O'Donnell, 2004). While activation of mPFC D2 receptors increases GABA release, 
reports on the effect of activation of D1 receptors on GABA release are mixed. Some 
studies have shown decreases or no effects on the release of GABA (Abekawa et al., 
2000; Grobin and Deutch, 1998; Retaux et al., 1991; Tseng and O'Donnell, 2007), 
while others have reported increases (Gorelova et al., 2002; Trantham-Davidson et al., 
2008). These discrepancies might be due to the decrease in extracellular glutamate 
after D1 activation, causing deactivation of GABAergic interneurons, or by the 
topographical differences (i.e. deeper vs. superficial layers of the mPFC) between 
studies. Thus in some cases, stimulation of D1 and D2 dopamine receptors in the mPFC 
appears to have possible opposite effects on GABA release.  
Similar, both excitatory and inhibitory effects have been suggested for the 
dopaminergic modulation of glutamatergic neuronal activity (Gulledge and Jaffe, 
2001; Penit-Soria et al., 1987). Also in this case, the opposite effects of dopamine 
release might be conveyed through activation of either D1 or D2 receptors. D2 receptor 
activation results in inhibition of pyramidal neurons, whereas activation of D1 
receptors results in excitation of pyramidal neurons especially when the neurons are in 
a depolarized state (Gulledge and Jaffe, 2001; Lavin and Grace, 2001; Yang and 
Seamans, 1996). The alleged modulatory function of prefrontal D4 receptors 
corroborates the evidence for the shifting role of dopamine (Wang et al., 2002; Yuen 
and Yan, 2009; Yuen et al., 2010). In addition, the amount of released dopamine has 
been shown to affect the activation of pyramidal neurons (Zheng et al., 1999). Low 
dopamine levels mediate excitatory effects via D1 receptors, whereas high dopamine 
concentrations inhibit pyramidal neurons via D2 receptors. 
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The primary mechanism for termination of the dopamine signal in most parts of the 
CNS is clearance, mediated by the dopamine transporter (DAT) (Cass et al., 1993; 
Eisenhofer et al., 2004; Giros et al., 1996) localized in the soma, dendrites, axons and 
axon terminals of dopamine neurons (Fig. 2.6) (Sotnikova et al., 2006). DAT rapidly 
uptakes most of the released dopamine, after which it is either packed into storage 
vesicles by vesicular monoamine transporter 2 (VMAT2) or metabolized to 3,4-
dihydroxyphenylacetic acid (DOPAC) by monoamine oxidase (MAO). In the PFC 
however, due to the weak effect of selective DAT inhibitors on extracellular dopamine 
and low immunoreactivity for DAT especially in the deep layers of the prelimbic 
cortex (Mundorf et al., 2001; Sesack et al., 1998), other mechanisms for regulating 
dopamine clearance has been suggested. These mechanisms include uptake into 
noradrenergic neurons by the noradrenaline transporter (NET) and uptake into glial 
cells and postsynaptic neurons by uptake2 mechanisms with subsequent metabolism by 
COMT or MAO (Dahlin et al., 2007; Mazei et al., 2002; Moron et al., 2002; Sesack et 
al., 1998). 
 
Figure 2.6. Dopaminergic synapse 
and the metabolism of dopamine in the 
striatum. The majority of released 
dopamine (DA) is taken up by 
dopamine transporters (DAT) into 
presynaptic dopaminergic neurons 
after which it is either packed to 
storage vesicles by vesicular 
monoamine transporter 2 (VMAT2) or 
metabolized to 3,4-dihydroxyphenyl-
acetic acid (DOPAC) by monoamine 
oxidase (MAO). However, some 
released dopamine is transported into 
glial cells and postsynaptic neurons by 
uptake2 mechanisms, where MAO and 
catechol-O-methyltransferase (COMT) 
are responsible for its metabolism to 
DOPAC, 3-methoxytyramine (3-MT) 
and homovanillic acid (HVA). 
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2.4.2  Noradrenaline & NET 
Noradrenaline has widespread projections throughout the brain and has been shown to 
play a role in working memory and attention regulation (Ramos and Arnsten, 2007). 
Pathologically, dysfuntions in the CNS noradrenergic neurotransmission has been 
associated with e.g. severe psychiatric disorders such as depression and anxiety as well 
as modulation of pain (Itoi and Sugimoto, 2010; Ossipov, 2010). Noradrenergic 
neurons arising from the LC modulate the activity of the mPFC by acting at different 
sub-types of adrenergic α1, α2 and β receptors (Ramos and Arnsten, 2007). The α2 
receptors, regarded as playing a crucial role in the activity modulation of the PFC, 
consist of three different subtypes: the most common subtype in the PFC, the α2A 
receptor, as well as α2B and α2C receptors. All three subtypes can be found 
postsynaptically, whereas only α2A, and to a lesser extent α2C, can be found 
presynaptically on noradrenergic cells and terminals (MacDonald et al., 1997). Out of 
all adrenergic receptors, noradrenaline has a preferable affinity for α2 subtypes and 
moderate levels of this neurotransmitter is considered to engage primarily postsynaptic 
α2 receptors (Aoki et al., 1994; Ramos and Arnsten, 2007; Wang et al., 2010b). The α1 
family consists similarly of three subtypes: the α1B receptors and the most common 
prefrontal cortical subtypes α1A and α1D (Day et al., 1997; Pieribone et al., 1994). 
With regards to adrenergic β receptors, the affinity of noradrenaline has been shown to 
be lower than for the α adrenergic subtypes. β adrenoceptors are divided into β1, β2 
and β3 receptors and they are expressed throughout the CNS with some regional 
specificity (Insel, 1993; Nicholas et al., 1993; Summers et al., 1995). The most 
prominent subtype in the PFC is the β1 receptor (Rainbow et al., 1984). In addition to 
neurons, β adrenoceptors have also been found on glial cells where activation of these 
receptors reduces the uptake of glutamate and regulates the availability of glucose 
(Fillenz et al., 1999; Hansson and Rönnbäck, 1991). Like the dopamine receptors, all 
subtypes of adrenergic receptors are G-protein-coupled and thus slow acting. 
Activation of α2 receptors decreases cyclic AMP (cAMP) signalling by inhibiting AC, 
whereas activation of β receptors increases cAMP signalling by AC stimulation. 
Activation of α1 receptors on the other hand activates phospholipase C (PLC) (Ordway 
et al., 1987; Ramos and Arnsten, 2007). 
Elevation in noradrenergic neurotransmission decreases the basal neuronal activity of 
the mPFC without altering the stimulus-evoked activity, consequently leading to an 
increase in cortical signal to noise ratio (Mantz et al., 1988; Thierry et al., 1992). The 
inhibition in the firing rate of pyramidal neurons is thought to be conveyed through 
increases in spontaneous GABAA receptor mediated inhibitory postsynaptic currents 
and through activation of postsynaptic α2 receptors (Kawaguchi and Shindou, 1998; 
Wang et al., 2010b). On the contrary, the activation of adrenergic α1 receptors has 
been shown to facilitate the release of glutamate from pre-synaptic terminals that 
synapse with apical dendrites of pyramidal neurons located in layer V of the mPFC, 
increasing the frequency of excitatory postsynaptic currents (Marek and Aghajanian, 
1999). With regards to behaviour, the stimulation of prefrontal cortical α1 receptors 
has been shown to impair cognitive functions in rats (Arnsten et al., 1999). In spite of 
high levels of β3 receptors in the PFC (Summers et al., 1995), evidence to date 
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indicates little to no influence of β adrenergic stimulation on PFC activity. Some 
behavioural studies have shown the beneficial effects of β2 stimulation (Ramos et al., 
2008) and detrimental effects of β1 stimulation (Ramos et al., 2005) on PFC cognitive 
function. However, the underlying neurochemistry behind these changes remains 
unclear. 
Furthermore, dopamine transmission in the mPFC appears to be regulated through 
noradrenergic neurons. As previously stated, the weak effect of DAT blockers and low 
levels of DAT in the PFC has led to the conclusion that NET acts as one of the key 
players in prefrontal cortical dopamine clearance. In fact, NET is widely distributed in 
the PFC (Schroeter et al., 2000) and surprisingly it has stronger affinity for dopamine 
than for noradrenaline (Giros et al., 1994; Gu et al., 1994). Additional support for the 
critical role of noradrenergic neurons in prefrontal cortical dopamine transmission was 
provided by Devoto et al. (2001), when the group discovered a co-release of both 
dopamine and noradrenaline from noradrenergic neurons in the mPFC (Devoto et al., 
2001). 
2.4.3  5-Hydroxytryptamine 
Dysregulation of CNS serotonin (or 5-hydroxytryptamine, 5-HT) has been 
traditionally linked to the etiology of mood and anxiety disorders such as depression 
and social anxiety, as well as the patophysiology of migraine and schizophrenia (Nutt 
and Stein, 2006; Pytliak et al., 2011). In general, 5-HT mediates effects by acting on 
numerous receptors (5-HT1-7) with multiple subtypes (Hoyer and Martin, 1997). 
Several 5-HT receptor subtypes from different families have been identified in the 
mPFC, on which serotonin, released from afferents from the raphe nuclei, acts to 
mediate both inhibitory and excitatory actions on neurons. All 5-HT receptors, apart 
from the 5-HT3 receptor classified as a ligand gated ion channel, are G-protein-
coupled (Maricq et al., 1991). AC inhibiting receptors include the 5-HT1 and 5-HT5 
families, whereas activation of 5-HT4, 5-HT6 and 5-HT7 families stimulates AC. The 
5-HT2 receptor family on the other hand does not affect AC, but activates PLC through 
Gq proteins (Hoyer and Martin, 1997; Nelson, 2004). 
Stimulation of mPFC 5-HT2 receptors, located mainly in the pyramidal cells and to a 
lesser degree in GABAergic interneurons, potentiates cortical glutamatergic activity 
through several mechanisms (Miner et al., 2003; Steketee, 2003; Willins et al., 1997). 
Firstly, although stimulation of 5-HT2 receptors has been reported to elevate 
extracellular GABA levels (Abi-Saab et al., 1999), the administration of 5-HT2A/C 
agonists increases glutamatergic neurotransmission by attenuating postsynaptic 
GABAA receptor currents in PFC pyramidal neurons (Feng et al., 2001). Secondly, 
similar to the effects of noradrenaline, stimulation of 5-HT2A receptors facilitates the 
glutamatergic transmission of pyramidal neurons as a result of increased frequency of 
excitatory postsynaptic currents in apical dendrites (Aghajanian and Marek, 1997). 
Thirdly, stimulation of 5-HT2 receptors promotes the release of glutamate from 
thalamic efferents to the mPFC (Marek and Aghajanian, 1998). Apart from these, 5-
HT1A receptors have also been localized to pyramidal neurons in the mPFC 
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(Pompeiano et al., 1992). Opposite to 5-HT2 receptors, the 5-HT1A and 5-HT6 receptors 
mediate mainly inhibitory effects on glutamatergic neurotransmission of mPFC 
pyramidal cells (Araneda and Andrade, 1991; Tassone et al., 2011). However, one 
recent study suggested an opposite effect, where activation of 5-HT1A receptors excites 
pyramidal cells through inhibition of fast-spiking inhibitory GABAergic neurons 
(Llado-Pelfort et al., 2011). With regards to 5-HT3 receptors, large proportions have 
been located mainly in GABAergic interneurons in superficial layers of the cingulate, 
prelimbic and infralimbic areas of the mPFC. The activation of these receptors inhibits 
pyramidal neurons in the mPFC, most likely via short lasting excitation of GABAergic 
inputs onto apical dendrites (Puig et al., 2004; Zhang et al., 2011). Earlier studies have 
also shown a direct and apparently delayed suppression of glutamatergic transmission 
in mPFC pyramidal cells after 5-HT3 stimulation (Liang et al., 1998). Modulation of 
prefrontal cortical GABAergic transmission can occur also via 5-HT4 receptors (Cai et 
al., 2002). Activation of these receptors causes bi-directional modulation of GABAA 
currents in prefrontal cortical pyramidal neurons, with enhancement of currents in 
some neurons and reduction in others. 
Furthermore, several groups have studied the effects of 5-HT receptors on dopamine 
transmission in the mPFC (Chen et al., 1992; Iyer and Bradberry, 1996; Matsumoto et 
al., 1999; Pehek et al., 2001; Sakaue et al., 2000; Schmidt and Fadayel, 1995; Tanda et 
al., 1994). These studies suggest that 5-HT1A/B/D, 5-HT3 and 5-HT6 receptor activation 
in general either stimulates or enhances dopamine release in the mPFC, while 
activation of 5-HT2A receptors primarily modulates, i.e. depending on the situation 
either stimulates or suppresses dopamine transmission.  
2.4.4. Histamine 
Histamine plays an important role in the CNS by regulating memory, cognition, 
emotion and sleep (Dere et al., 2010). Dysfunctions in this system has thus been 
previously reported to be at least partly involved in the patophysiology of disorders 
related to these functions and processes (Haas et al., 2008). Histamine mediates its 
effects by acting on four different G-protein coupled histamine receptors (H1-H4) 
(Haas et al., 2008). Expression of H1, H2 and H4 receptors has been discovered 
throughout the body, whereas H3 receptors are nearly exclusive to the CNS 
(Airaksinen et al., 2006; Bakker et al., 2002). Stimulation of H1 and H2 receptors leads 
to activation of PLC or increases in cAMP signalling by AC stimulation, respectively 
(Haas et al., 2008). Stimulation of presynaptic H3 receptors on the other hand, leads to 
AC inhibition through Gi proteins. The function of H3 receptors is to modulate central 
neurotransmission by mediating inhibitory actions on the synthesis and release of 
histamine and the release of several other neurotransmitters, such as acetylcholine, 
GABA and glutamate. Accordingly, the inhibition of H3 receptors in cortical neurons 
in vitro results in an increase in both GABA and glutamate levels (Dai et al., 2006). 
In the PFC, abundant expression of H3 receptors has been located in both intrinsic 
GABAergic interneurons and also in glutamatergic terminals running from the 
thalamus (Jin and Panula, 2005; Pillot et al., 2002). It is also possible that H3 receptors 
  17 
are expressed on prefrontal pyramidal neurons projecting to the tuberomammillary 
hypothalamic region (Flik et al., 2011). Although H3 stimulation is generally accepted 
to decrease neurotransmitter release, potassium-stimulated prefrontal GABA release 
has been shown to increase after systemic H3 stimulation and to decrease as a 
consequence of systemic H3 inhibition (Giorgetti et al., 1997; Welty and Shoblock, 
2009). These paradoxical effects corroborate the modulatory role of H3 receptors and 
might be a result of actions on postsynaptic H3 receptors on GABAergic interneurons, 
or as a downstream effect of H3 receptors on other neurotransmitters. It has to be noted 
however, that H3 inhibition did not affect basal levels of glutamate or GABA (Welty 
and Shoblock, 2009). In addition, extracellular prefrontal histamine levels have been 
shown to decrease after both systemic and local administration of a selective H3 
agonist (Flik et al., 2011). With regards to behaviour, the histaminergic connections 
running from the tuberomammillary hypothalamic region to the mPFC might be 
related to the regulation of social behaviour and emotion as histamine elevates 
prefrontal cortical vasopressin that in turn modulates in particular fear, aggression, and 
anxiety (Cacabelos et al., 1987; Zink et al., 2010). 
2.4.5  Glutamate 
The excitatory neurotransmitter glutamate is the most prominent neurotransmitter in 
the mammalian brain and it exerts actions through groups and subtypes of ionotropic 
and metabotropic receptors (Table 2.2; Kuzmiski and Bains, 2010; Stawski et al., 
2010). Increased glutamatergic neurotransmission underlies a number of pathological 
conditions, epilepsy being probably the best characterized of these (Raiteri, 2006). 
Other CNS disorders where glutamate plays a role in the patophysiological 
mechanisms include e.g. stroke, migraine, depression and neuropathic pain (Bowie 
2008). 
Table 2.2. Glutamate receptors and subtypes. 
 
 Receptor Subtype 
NMDA GluN1, GluN2A-2D, GluN3A-3B 
AMPA GluA1-A4 
Ionotropic 
kainate GluK1-K5 
I mGlu1, mGlu5 
II mGlu2, mGlu3 
Metabotropic 
III mGlu4, mGlu6, mGlu7, mGlu8 
The ionotropic glutamate receptors are rapidly acting cation selective ion channels. 
The group I metabotropic receptors on the other hand activate PLC through Gq 
proteins, whereas groups II and III inhibit AC through Gi proteins. All groups of 
ionotropic receptors are localized in the mPFC and they are distributed 
homogeneously with some subtype exceptions (Brene et al., 1998; Conn and Pin, 
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1997). The recurrent collaterals of pyramidal neurons in the mPFC mediate actions 
both via NMDA and AMPA receptors, whereas the projections from the MD signal 
predominantly via AMPA receptors (Pirot et al., 1995). Several subtypes of 
metabotropic receptors have also been found in the mPFC located both in pyramidal 
and non-pyramidal neurons (Ohishi et al., 1993; Ohishi et al., 1995; Simonyi et al., 
2005). 
Glutamate in the mPFC is released from terminals arising from the thalamus, cortex 
and limbic structures. The release of glutamate from these terminals, connected to both 
pyramidal glutamatergic neurons and GABAergic interneurons, increases extracellular 
GABA through activation of AMPA receptors (Bacon et al., 1996; Carr and Sesack, 
1998; Del Arco and Mora, 1999; Pinto et al., 2003). Also prefrontal dopamine levels 
have been shown to increase after infusion of AMPA and kainate agonists (Jedema 
and Moghddam, 1996). NMDA activation on the other hand produces biphasic effects 
on dopamine transmission in the mPFC: A high concentration of intracranial NMDA 
has been reported to increase extracellular dopamine, whereas low NMDA 
concentrations decrease dopamine levels (Feenstra et al., 1995). In addition, the 
activation of prefrontal cortical metabotropic receptors has been shown to enhance 
NMDA induced currents and to regulate the expression and phosphorylation of 
NMDA receptors (Wirkner et al., 2007; Xi et al., 2011) 
2.4.6  Acetylcholine 
The cholinergic system is implicated in many functional, behavioural and pathological 
states characterized by various degrees of cognitive impairment. Cholinergic 
innervation of the mPFC originates from the brainstem and basal forebrain: 
specifically, the mesopontine laterodorsal nucleus and nucleus basalis magnocellularis 
respectively (Lehmann et al., 1980; Satoh and Fibiger, 1986). These afferents have 
been reported to synapse on both pyramidal neurons and non-pyramidal interneurons 
(Houser et al., 1985). Degeneration of the cholinergic system, particularly in the basal 
forebrain, has been linked to many diseases such as Alzheimer’s disease, Parkinson’s 
disease and schizophrenia (Lucas-Meunier et al., 2003). 
In addition to the thalamocortical inputs, acetylcholine is released from local circuit 
interneurons in the PFC (Mansvelder et al., 2006). Like glutamate receptors, 
acetylcholine receptors can be divided into ionotropic (=nicotine) receptors and 
metabotropic (=muscarine) receptors (Lucas-Meunier et al., 2003). Nicotinic receptors 
are ligand-gated ion channels and they are classified on the basis of subunits. Neuronal 
nicotinic receptors have a pentameric structure composed of α and β subunits. To date, 
nine α (α2-10) and three β (β2-4) subunits have been identified. Most often the receptor 
is comprised of two α and three β subunits, but especially α7, α8 and α9 subunits can 
build functional homooligomers. Muscarinic receptors on the other hand are G-
protein-coupled and form two different families, the M1- and M2-like receptors. The 
M1-like family consists of M1, M3 and M5 subtypes that stimulate the phosphoinositol 
pathway through Gq proteins, whereas the M2-like family consists of M2 and M4 
subtypes that inhibit AC through Gi proteins.  However, muscarinic receptors have the 
  19 
ability to signal via multiple pathways and therefore these specificities cannot be 
considered absolute (Felder, 1995; Nathanson, 2000). 
In the mPFC, nicotinic receptors containing α4β2 subtypes have been shown to 
increase extracellular glutamate and facilitate the activation of pyramidal neurons by 
glutamatergic thalamocortical afferents possibly through presynaptic actions (Gioanni 
et al., 1999; Lambe et al., 2003; Vidal and Changeux, 1993). Suggestions of similar 
mechanisms in thalamocortical modulation of cortical interneurons by nicotinic 
receptors have also been presented (Mansvelder et al., 2006). Indeed, fast-spiking 
GABAergic interneurons have been shown to express both α4 and β2 subunits in 
addition to α7 subunits (Couey et al., 2007). Activation of these receptors in PFC 
dopaminergic and glutamatergic afferents has also been proposed to induce 
acetylcholine release from basal forebrain projections to the mPFC (Briand et al., 
2007). Also dopamine and noradrenaline transmissions are modulated by nicotinic 
receptors. Local nicotine administration increases extracellular dopamine and 
noradrenaline in the mPFC (Shearman et al., 2005), whereas selective β2 and α7 
activation increases exclusively extracellular dopamine (Livingstone et al., 2009). 
Nicotinic receptor activation can also influence prefrontal cortical 5-HT levels through 
increases in serotonin transporter (SERT) activity (Awtry and Werling, 2003; Awtry et 
al., 2006). 
The M1 subtype is the most abundant muscarinic receptor in the forebrain (Levey et 
al., 1991; Ma et al., 2003; Wei et al., 1994). These receptors have been localized to 
proximal apical dendrites of pyramidal neurons in the mPFC, where they mediate 
direct excitatory effects and increase excitatory synaptic currents in the cells leading to 
tonic firing (Carr and Surmeier, 2007; Chessell et al., 1993; Dijk et al., 1995; Gulledge 
et al., 2009; Shirey et al., 2009; Vidal and Changeux, 1993). With regards to dopamine 
and acetylcholine, local muscarinic stimulation has been reported to increase the efflux 
of both neurotransmitters in the mPFC through direct stimulation of M1 receptors (Li 
et al., 2005; Li et al., 2009). Besides M1 receptors, the M3 receptor has been shown to 
regulate the output of mPFC pyramidal neurons via tonic suppression of the 
afterhyperpolarization in layer V pyramidal neurons (Gulledge et al., 2009). Activation 
of prefrontal cortical M2 receptors, expressed both pre- and postsynaptical 
compartments of glutamatergic synapses (Volpicelli and Levey, 2004), has on the 
other hand been reported to mediate long-term suppression of the synaptic efficacy in 
hippocampal efferents to the mPFC (Wang and Yuan, 2009) In addition, non-selective 
activation of muscarinic receptors has been shown to enhance insulin gated inhibitory 
GABAA currents in pyramidal neurons of the PFC (Ma et al., 2003). 
2.4.7  GABA 
GABAergic reduction of excitatory output in the mPFC is conveyed mainly by local 
interneurons described earlier in this review (see section 2.3.1). The released GABA 
exerts both direct and indirect inhibitory actions through either ionotropic GABAA or 
metabotropic GABAB receptors localized on pyramidal neurons and GABAergic 
interneurons in the mPFC (Dunn et al., 1996; Margeta-Mitrovic et al., 1999). Deficits 
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in CNS GABA receptors have been linked to the etiology of a variety of 
neuropsychiatric disorders including anxiety, epilepsy, depression and drug addiction 
(Moult 2009; Ong and Kerr, 2005). 
Like the nicotine receptors for acetycholine, the GABAA receptors act as ligand-gated 
ion channels and consist of five protein subunits arranged around a central pore 
mediating tonic inhibition of target neurons (Farrant and Nusser, 2005; Mohler, 2006). 
Activation of metabotropic GABAB receptors on the other hand hyperpolarizes the 
neuronal membrane through Gi proteins. The majority of postsynaptic GABAB 
receptors are located outside the synapse and therefore activated likely by pooling of 
ambient GABA (Kulik et al., 2003; Kulik et al., 2006; Wang et al., 2010a). 
Stimulation of GABAB receptors reduces both basal and amphetamine induced 
dopamine release in the mPFC (Balla et al., 2009), whereas reducing GABA activity 
through local GABAA antagonists increases phasic dopamine release (Enomoto et al., 
2011). This effect is probably mediated via activation of glutamatergic efferents that 
synapse onto VTA dopamine neurons, in turn projecting back to the PFC. 
The VTA forms another source of prefrontal GABA. The activity modulating effect of 
these GABAergic afferents is conveyed through direct inhibition of pyramidal neurons 
and through indirect disinhibition inhibiting the inhinbitory local circuit neurons in the 
mPFC (Carr and Sesack, 2000a; Yokofujita et al., 2008). 
2.5 COMT and the prefrontal cortex 
As discussed previously, the mechanisms for prefrontal dopamine clearance include 
uptake into noradrenergic neurons by NET and uptake into glial cells and postsynaptic 
neurons by a high-capacity monoamine transporter system (uptake2) with subsequent 
metabolism by COMT or MAO (Dahlin et al., 2007; Mazei et al., 2002; Moron et al., 
2002). Uptake2 mechanisms consist of several different transport proteins including 
the extraneuronal monoamine transporter (EMT) and the neuronal plasma membrane 
monoamine transporter (PMAT), both of which are widely expressed in a number of 
tissues (Dahlin et al., 2007; Martel and Azevedo, 2003). Particular richness of uptake2 
proteins can be seen in the cortical areas of the brain, reflecting the importance of the 
uptake2-COMT pathway in the PFC. As for the role of COMT, 3-methoxytyramine (3-
MT), a putative COMT product, has been found to comprise more than 60 % of total 
dopamine turnover in the PFC (Karoum et al., 1994). Further evidence emphasizing 
the importance of COMT in the regulation of synaptic dopamine and prefrontal 
physiology was provided by Yavich et al. (2007), who showed that a lack of COMT 
delays dopamine clearance and increases signal-evoked dopamine release by 20-25 % 
in the PFC, but not in the striatum. 
The human COMT gene, located on chromosome 22, contains several single 
nucleotide polymorphisms (SNP), one of which has been studied widely for its 
association with psychiatric disorders and prefrontally mediated cognition (Dickinson 
and Elvevåg, 2009; Tunbridge, 2010). This polymorphism, referred to as Val/Met, is 
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found only in humans and determined by a guanine to adenine substitution in codon 
158 in MB-COMT and codon 108 in S-COMT, encoding either valine or methionine 
in the final product (Lachman et al., 1996; Lotta et al., 1995). The physiological 
impact of this SNP is detected as higher thermolability and subsequently lower 
enzyme activity in Met carriers than in those individuals homozygous for the Val 
allele. In fact, according to Chen et al. (2004), the activity in post-mortem PFC of Met 
homozygotes was reduced by 30-40 %. The change in prefrontal COMT activity 
suggests that the thermolabile Met-allele is associated with a tendency for higher 
synaptic dopamine levels and increased dopaminergic signaling than the more stable 
Val-allele. Val/Met polymorphism has also been shown, probably as a downstream 
consequence of altered prefrontal COMT activity, to affect midbrain dopamine 
biosynthesis via tyrosine hydroxylase gene expression (Akil et al., 2003). 
Due to close involvement of COMT in the modulation of PFC dopamine and the 
genetic variation of enzyme activity, the number of association studies exploring the 
clinical impact of Val/Met has increased rapidly during recent years. Although several 
studies have been controversial, some associations have also been reported: The Met 
allele, although beneficial for working memory and executive function, has been 
implicated with obsessive compulsive disorder in men, anxiety in women, panic 
disorder, impaired emotional processing as well as aggressive and antisocial behaviour 
in schizophrenic patients (reviewed by Dickinson and Elvevåg, 2009; Tunbridge et al., 
2006; Tunbridge, 2010). The Val allele on the other hand, has been implicated as a 
weak risk factor for schizophrenia and with psychotic symptoms both in Alzheimer’s 
patients and in young adults with a history of adolescent cannabis abuse (discussed in 
section 6.4). In addition, also the cognitive response to atypical antipsychotics in 
schizophrenic patients seems to be influenced by Val/Met polymorphism (Woodward 
et al., 2007). 
Although COMT genotype seems to affect several mental processes related to PFC 
function, pinpointing detrimental or beneficial effects on a single gene is an 
oversimplification. Moreover, the influence of an individual’s COMT genotype will 
also depend on the nature of the task and other factors related to PFC state (Tunbridge 
et al., 2006). 
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3   AIMS OF THE STUDY 
COMT has gained considerable attention because of its distinct role in prefrontal 
dopamine metabolism. Genetic polymorphisms, affecting COMT activity and 
subsequently prefrontal dopamine metabolism in particular, have led to suggestions of 
COMT being a susceptibility gene in e.g. cognitive dysfunctions in schizophrenia and 
cannabis abuse. We have now applied several in vivo methods to study the 
physiological role of COMT in L-dopa and dopamine metabolism with a main 
emphasis on prefrontal dopamine (Fig. 3.1). The specific aims of the study were: 
I To study how a lack of the S-COMT isoform affects the total activity of 
COMT and the pharmacokinetics of orally administered L-dopa. 
II To clarify the role of COMT isoforms in the regulation of L-dopa-
induced extracellular striatal, accumbal and prefrontal dopamine 
transmission. 
III To quantify the role of COMT in basal prefrontal dopamine 
transmission and dopamine metabolism in the medial prefrontal cortex 
during inhibition of the dopamine transporter (DAT), noradrenaline 
transporter (NET) or monoamine oxidase (MAO). 
IV To investigate how COMT inhibition affects striatal and accumbal 
dopamine turnover after Δ-9-tetrahydrocannabinol (THC) 
administration. 
Figure 3.1. The dopaminergic synapse and the 
metabolism of dopamine (DA) in the prefrontal cortex, 
where the clearance of released dopamine (DA) may 
occur via several of the following mechanisms: Uptake 
into pre- or postsynaptic neurons or glial cells by 1) the 
dopamine transporter (DAT), 2) the noradrenaline 
transporter (NET) or 3) uptake2 mechanisms with 
subsequent metabolism by 4) monoamine oxidase (MAO) 
or 5) catechol-O-methyltransferase (COMT). Because of 
their tentative nature, we aimed to quantify the role of 
these pathways and those of distinct proteins involved in 
prefrontal dopamine metabolism. 3-MT, 3-methoxy-
tyramine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, 
homovanillic acid; VMAT2, vesicular monoamine 
transporter 2. 
  23 
4   MATERIALS AND MAIN METHODS 
4.1  Animals and genotyping 
Both female and male homozygous COMT knockout (COMT-KO) and S-COMT 
deficient mice as well as their wild type (Wt) littermates were used in Studies I-III. 
Male C57BL6 Wt mice were used in Study IV. The generation of COMT-KO mice on 
a mixed 129Sv x C57BL6 background was originally described by Gogos et al. 
(1998). Detailed description of the generation of S-COMT deficient mice can be found 
in Study I. Briefly, the transcription of S-COMT mRNA was prevented by a mutation 
of the methionine coding start codon (ATG) to threonine (ACC) in the Comt gene 
(Fig. 4.1). As a result no soluble COMT is expressed and the sequence is changed by 
one amino acid in the membrane-bound form. The mutation in MB-COMT however, 
is conservative as methionine and threonine both are α-helix forming uncharged 
residues of relatively similar size. Also, this mutation is located at the end of the helix 
that links the soluble domain to the transmembrane helix. It is buried between the bulk 
of protein and the membrane, far enough from any catalytic or binding domains and 
relatively inaccessible (Bai et al., 2007). 
 
Figure 4.1. The mouse Comt gene and mutation of the S-COMT start codon. Modified from Tunbridge 
et al. (2006). 
COMT-KO mice were genotyped as previously described by Tammimäki et al. (2008). 
Genotyping of S-COMT deficient mice was conducted using PCR using two designed 
primers (Table 4.1) on DNA samples isolated from tail biopsies described originally 
by Laird et al. (1991). Met2 mutation on the PCR product was confirmed by digesting 
with the additional restriction site BshTI (absent in Wt sequence), by standard 
conditions. Mice were bred in the Laboratory Animal Centre in University of Helsinki, 
Finland (Studies I-III) or obtained from Charles River (Study IV). To keep the COMT 
deficient strains viable, they were enriched regularly by mating C57BL/6J females  
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Table 4.1. Primers used in genotyping S-COMT deficient mice. 
 
Primer Sequence 
BspF-Aco 5’-TGAGTGCTTACCTTGTACACAT-3’ 
BspER-MpH 5’-CCTTACTGCTCTCCGGACCA-3’ 
obtained from Harlan, The Netherlands, with heterozygous males. All mice were 
housed in groups of two-eight animals per cage at an ambient temperature of 21-23 ºC 
with free and continuous access to food pellets and drinking fluid.  The light/dark 
cycle was kept at 12/12 h with lights on from 6 AM to 6 PM. The animals used in 
experiments were two-eight months of age. All procedures in Studies I-III were 
performed according to European Community Guidelines for the use of experimental 
animals (European Communities Council Directive 86/609/EEC) and the experimental 
setup was reviewed by State Provincial Office of Southern Finland and approved by 
the Animal Experiment Board in conformance with the current legislation. The 
procedures in Study IV were conducted in accordance with the UK Animals 
(Scientific Procedures) Act 1986 and associated Home Office Guidelines. 
4.2  Drugs and treatments 
L-Dopa (Sigma, St. Louis, MO, USA) and dopa decarboxylase (DDC) inhibitor 
carbidopa (Orion, Espoo, Finland) were suspended in a 0.25 % carboxymethyl 
cellulose (Fluka, Steinheim, Germany) gel that was given either p.o. in the 
pharmacokinetic experiment (Study I) or i.p. in the microdialysis experiment (Study 
II). GBR 12909 (Tocris, Avonmouth, UK), reboxetine (Toronto Research Chemicals, 
North York, Canada) and pargyline (Sigma) were dissolved in saline (0.9 % NaCl) and 
given i.p. in the PFC microdialysis study (Study III). Δ-9-Tetrahydrocannabinol (THC; 
Study IV; Tocris) stock was administered in a vehicle consisting of 5% ethanol, 5% 
Tween-80 (Sigma) and 90% 0.9% w/v saline. Tolcapone (Study IV; Roche) was 
dissolved in a 20 % cyclodextrin (Acros, New Jersy, NJ, USA) solution. All injections 
were given in a volume of 10 ml/kg (i.p.) or 5 ml/kg (p.o.). Drug doses were calculated 
as free base. 
4.3  COMT activity assay (Study I) 
After decapitation of the mice, the brain was rapidly excised, rinsed with ice-cold 
physiological saline solution, and placed on an ice cooled coronal mouse brain matrix 
(Stoelting, Wood Dale, IL, USA). Following dissection of the striatum, mPFC, 
duodenum and liver, the tissues were immediately placed in frozen centrifuge tubes to 
be cooled on dry ice. Samples were stored in -80 ºC until assayed. The COMT activity 
assay is described in more detail in Study I. Briefly, the enzyme preparation was 
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incubated at 37 ºC in 100 mM phosphate buffer (pH 7.4) containing 5 mM MgCl2, 200 
µM S-adenosyl-L-methionine (Sigma) and 500 µM 3,4-dihydroxybenzoic acid 
(Sigma) as a substrate. The reaction products, vanillic and isovanillic acid were 
analyzed by an HPLC system with electrochemical detection. Total COMT activity 
was expressed as picomols vanillic and isovanillic acid formed in one min per mg of 
protein in the sample. 
4.4  Assay of monoamines in plasma and tissue samples (Study I) 
To study the pharmacokinetics of L-dopa, the mice were fasted for 12 h prior to the 
experiment. After this period, the animals were given simultaneous oral L-Dopa (10 
mg/kg) and carbidopa (30 mg/kg) suspensions with a plastic gastric tube (Agn Tho’s 
AB, Lidingö, Sweden). From each individual mouse, two blood samples were 
collected by Microvette capillary blood collection tubes (Sarstedt, Nümbrecht, 
Germany) so that at least six results were obtained at each time-point (0, 30, 60, 90 
and 120 min). The first blood sample was taken from the saphenous vein and the 
second, terminal sample, from the jugular vein. Following collection, the blood 
samples were centrifuged at 4900 X g at 4 °C for 10 min and the plasma was frozen 
and stored in -80 °C. After the terminal blood sample, the mice were killed by 
decapitation, where after the liver, duodenum, striatum and mPFC was rapidly 
dissected, frozen in centrifuge tubes placed on dry ice and stored in -80 °C. The tissues 
were later analyzed for L-dopa, 3-O-methyldopa (3-OMD), dopamine, DOPAC and 
HVA by high-performance liquid chromatography (HPLC) combined with 
electrochemical detection. The concentrations of analytes were reported as ng/ml of 
plasma or ng/mg of tissue. Detailed description of the HPLC analysis can be found in 
Study I. 
4.4.1  Methodological considerations 
The animals were fasted for 12 h prior to the experiment to avoid pharmacokinetic 
interactions and overfilling the stomach during gavage. However, the possibility of 
coprophagy, quite common in rodents, cannot be ruled out. Another factor affecting 
results are the reduced basal metabolic rates that fasting might lead to (Bjorntorp and 
Yang, 1982). In addition, parameters related to absorption might be influenced by 
population variability, though this most likely not an issue within inbred mouse 
strains. 
 
The limitations in sample collection are mainly related to the risk of blood coagulation 
and to the dissection technique. Blood coagulation was inhibited by 3K-EDTA coated 
collection tubes. The striatum was dissected by punching and the mPFC was dissected 
by cutting. It has to be noted, that both these techniques might cause small variation 
and bias to the brain region analyzed. 
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4.5  Immunoblotting (Study I) 
Western immunoblotting was performed on individual liver samples from one 
randomly selected male and one randomly selected female from each genotype 
(COMT-KO, S-COMT deficient and Wt mice). First the samples were diluted 1:20 
with a homogenization buffer (10 mM Na2HPO4, pH 7.4, containing 0.5 mM 
dithiothreitol) and subsequently homogenized using a sonicator (Rinco Ultrasonics 
sonicator, Arbon, Switzerland). The homogenates were then centrifuged at 890 X g at 
+4 °C for 10 min and the supernatants were collected. After this, the 20 µg samples 
were diluted with Laemmli buffer, loaded and electrophoresed in a 12 % SDS-
polyacrylamide gel. Subsequently, samples were transferred onto Protran® 
nitrocellulose transfer membrane (Schleicher & Schuell Bioscience GmbH, Dassel, 
Germany) and after blocking non-specific binding with 5 % non-fat dry milk in Tris-
buffered saline (TBS), the membranes were incubated with mouse anti-COMT 
monoclonal antibody (1:10 000; BD Bioscience Pharmingen, San Diego, CA, USA). 
Following this, the membranes were incubated with a goat anti-mouse horseradish 
peroxidase conjugate (1:2000; R&D Systems, Minneapolis, MN, USA). Bands of the 
blots were visualized by chemiluminescent substrate (Thermo scientific, Rockford, IL, 
USA) on a GeneGnome chemiluminescent detector (SynGene, Synoptics LTD, UK). 
4.6  Immunohistochemistry (Studies I and III) 
COMT immunohistochemistry (Study I) and NET immunofluorescence (Study III) 
was preformed with slight modifications from the protocol described by Myöhänen et 
al. (2008). DAT immunohistochemistry (Study III) was performed as described earlier 
(Mijatovic et al., 2007). The specificities of COMT (Myöhänen et al, 2010), DAT 
(Reveron et al., 2002) and NET (Mundorf et al., 2001) antibodies have been proven 
and are reported elsewhere. More detailed description of the method and 
characterization of the antibodies can be found in the supplementary material of 
studies I and III. 
4.7  In vivo microdialysis (Studies II, III and IV) 
4.7.1  Stereotactic surgery 
The stereotactic surgery was conducted under general isoflurane (4 % induction, 2 % 
maintenance) and local lidocaine anaesthesia using a stereotactic frame (Stoelting, 
Wood Dale, IL, USA). The mice were also given pre and post surgery buprenorphine 
(0.1 mg/kg, s.c.) for analgesia. The guide cannulas were aimed at the point above the 
dorsal striatum (A/P = +0.6, L/M = +1.8, D/V = -2.2), NAcc (A/P = +1.4, L/M = +0.9, 
D/V = -3.8) or the mPFC (A/P = +2.0, L/M = +0.5, D/V = -1.0) according to the 
mouse brain atlas by Franklin and Paxinos (1998). After the surgery the mice were 
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housed individually in test cages and allowed to recover for five-seven days before the 
experiment. 
4.7.2  Conventional microdialysis 
In the morning of the experiment day (at 8 a.m.), a microdialysis probe (MAB-4, Agn 
Tho’s AB, Lidingö, Sweden; membrane length 1 mm for NAcc and dorsal striatum 
and 2 mm for PFC, outer diameter 0.2 mm) was inserted into the guide cannula 
described in the previous section.  The probe was perfused with Ringer’s solution at a 
flow rate of 2 µl/min and four baseline samples (every 20 min, 40 µl/sample) were 
collected after a 120 min stabilization period. The obtained dialysates were separated 
by high performance liquid chromatography (HPLC) and quantified by and 
electrochemical detector. More detailed description of in vivo microdialysis, schedules 
for drug administration and HPLC analysis can be found in respective studies. At the 
end of the experiment, the animals were decapitated and the brains were removed from 
the skull and frozen rapidly on dry ice. The positions of the probes were verified 
histologically from brain slices prepared post mortem. 
4.7.3  No-net-flux microdialysis 
For description of the probe insertion, see section 4.7.2. After insertion, the probe was 
perfused at a flow rate of 0.6 µl/min and three baseline samples (30 min, 18 µl) were 
collected after a 180 min stabilization period. Thereafter, four different concentrations 
(0, 2, 10 and 20 nM) of dopamine in Ringer’s solution were perfused through the 
probes in random order. Following a 30 min equilibration period, two 30 min samples 
were collected at each perfusion concentration for HPLC analysis. At the end of the 
experiment, the animals were sacrificed as described earlier in section 4.7.2. 
4.7.4  Methodological considerations 
In microdialysis, a small probe containing a semi-permeable membrane mimicking the 
function of a blood vessel is introduced into the area to be studied (Zetterström et al., 
1983). The main advantage of the method is the ability to monitor awake animals for 
long time periods. The disadvantages on the other hand, include the poor time 
resolution (20 min) of sampling and the mechanical damage to tissues. 
4.8  Data analysis and statistics 
The tissue monoamines (L-dopa, 3-OMD, dopamine, DOPAC and HVA) were 
analyzed calculating the area under the concentration-time curve (AUC) between 0 
and 120 min according to the trapezoidal rule, and comparing these results using two-
way ANOVA with sex and genotype as independent variables. COMT activities were 
also compared with two-way ANOVA with sex and genotype as independent 
variables. Both analyses were followed by Scheffe’s test in cases where appropriate. 
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Conventional microdialysis data in the study on the effect of S-COMT deficiency on 
L-dopa induced dopamine and metabolite levels were analyzed calculating the AUC 
after L-dopa administration, and comparing the values with one-way ANOVA. The 
data from all microdialysis studies using COMT-KO mice were analyzed by one- or 
two-way ANOVA for repeated measures with treatment or sex and genotype as 
independent variables. Bonferroni comparisons were used as post hoc tests where 
appropriate. Drug effects of tolcapone and THC were examined using repeated-
measures ANOVA comparing of the sum of the three samples prior to drug 
administration with the sum of the three samples following drug administration. For 
the effects of tolcapone, subjects were pooled into two groups, based on whether their 
first injection was vehicle or tolcapone, since THC was given only after the tolcapone 
post-drug interval. Significant interactions were explored using LSD post-hoc tests. 
In the no-net-flux study, a linear equation was constructed for each animal by plotting 
the difference in perfused (DAin) and obtained (DAout) dopamine concentrations for 
each perfusion concentration (DAin) first described by Lönnroth et al. (1987). Based on 
this equation, the extracellular dopamine level (DAext) and the in vivo extraction 
fraction (Ed) were calculated. The DAext value stands for the perfusion fluid dopamine 
concentration at which there is no net flux of dopamine through the probe (DAin - 
DAout = 0), whereas Ed has been shown to describe especially the clearance of 
neurotransmitters (Parsons and Justice, 1992; Smith and Justice, 1994). Two-way 
ANOVA was used to further analyze the no-net-flux data with sex and genotype as 
independent variables. 
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5   RESULTS 
5.1  COMT activity in S-COMT deficient mice (Study I) 
First, we wanted to determine how much a lack of S-COMT would decrease the total 
COMT activity ex vivo. Indeed, S-COMT deficiency clearly and significantly 
decreased the total hepatic COMT activity in both sexes (by 74 % in females and 53 % 
in males; Fig. 5.1A) when compared to Wt littermates. Also duodenal COMT activity 
was decreased in the S-COMT deficient animals (by 56 and 78 % in females and 
males, respectively; Fig. 5.1B). With regards to sex differences, the activity was 
generally lower in females than in males, with the exception of duodenal activity in S-
COMT deficient mice. Also in the brain areas tested, a reduction of about 65 % in total 
COMT activity in S-COMT deficient animals was observed (Fig. 5.1C/D). However, 
no sex-related differences were found. COMT-KO animals had no detectable COMT 
activity in any tissue or region studied. 
 
Figure 5.1. Total COMT activities in the liver (A), duodenum (B), striatum (C) and prefrontal cortex 
(D) of S-COMT deficient mice (S-COMT) and their wild type (Wt) littermates. +P < 0.05 and +++P < 
0.001 differs significantly from corresponding male, ***P < 0.001 differs significantly from 
corresponding Wt. Values are mean ± SEM from 6-12 animals. 
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5.2 Pharmacokinetics of oral carbidopa/L-dopa in COMT-KO and 
S-COMT deficient mice (Study I) 
5.2.1  Peripheral tissues 
Plasma L-dopa was increased in both sexes and all genotypes after a single oral dose 
of carbidopa/L-dopa (30/10 mg/kg). Both in Wt and S-COMT deficient animals the 
peak values (Cmax) were reached at 30 min post administration, whereas in COMT-KO 
mice, the peak was seen at 60 min post administration. The apparent increase 
confirmed by the AUC values (Fig. 5.2A), was about 55 % higher in COMT-KO mice 
and about 30 % higher in S-COMT deficient mice than in their Wt littermates. With 
regards to sex differences, the absence of COMT prolonged the elimination of plasma 
L-dopa only in males (Study I, Fig. 3). The hepatic L-dopa levels followed closely the 
corresponding levels in the plasma (Fig. 5.2B), whereas duodenal L-dopa 
concentrations were elevated only in male mice (up by 141 % in male COMT-KO and 
by 54 % in S-COMT deficient mice; Fig. 5.2C). Basal peripheral L-dopa levels were 
very low and no genotype related differences were seen. 
 
Figure 5.2. Plasma (A), liver (B) and duodenal (C) L-dopa area under the concentration curve (AUC) 
values in wild type (Wt), S-COMT deficient and COMT knockout (COMT-KO) mice after a single oral 
dose of carbidopa/L-dopa (30/10 mg/kg). +P < 0.05 differs significantly from corresponding male, 
**P < 0.01 and ***P < 0.001 differs significantly from corresponding Wt, #P < 0.05 and ##P < 0.01 
differs significantly from corresponding S-COMT deficient mouse. Values are mean ± SEM from 6-13 
animals. 
3-OMD levels in the peripheral tissues were reduced in both sexes as a function of 
decreasing COMT protein and no 3-OMD was found in the COMT-KO mice (Study I, 
Fig. 4). In Wt mice, the levels of 3-OMD, and respective AUC values, were lower in 
females than in corresponding males. 
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5.2.2  Brain tissues 
In the brain, L-dopa levels did not display any sex or genotype effects. Generally, the 
Cmax values were seen later than in peripheral tissues. Central 3-OMD levels behaved 
similarly to the levels in plasma and peripheral tissues, with Wt mice having the 
highest 3-OMD concentrations. 
In females, AUC values for striatal dopamine were significantly higher than Wt values 
only in COMT-KO animals (up by 26 %, p < 0.05; Table 5.1), whereas in the mPFC, 
levels were elevated both in COMT-KO and S-COMT deficient mice (up by 80 %, p < 
0.01 and 59 %, p < 0.05, respectively). In males, dopamine levels both in the mPFC 
and striatum were statistically unaffected by genotype. Striatal DOPAC values were 
elevated in female S-COMT deficient mice (up by 77 %) and in both sexes of COMT-
KO mice when compared to Wt animals. In the mPFC, DOPAC levels were higher in 
both sexes of both S-COMT deficient (up by 95 % in males and 153 % in females) and 
COMT-KO mice than in corresponding Wt mice. Reduction of striatal HVA values 
was seen in both sexes of S-COMT deficient animals (59 % in males and 31 % in 
females), but in the PFC, a significant decrease of 48 % was only seen in males. No 
HVA was detected in the COMT-KO animals. 
Table 5.1. Area under the concentration curve (AUC) values for dopamine in the striatum and medial 
prefrontal cortex (mPFC) in each genotype and both sexes after oral administration of carbidopa/L-
dopa (30/10 mg/kg). Wt = wild type, COMT-KO = COMT knockout mice. *P < 0.05 and **P < 0.01 
differs significantly from corresponding Wt, #P < 0.05 differs significantly from corresponding S-
COMT deficient mouse,  +P < 0.05 differs significantly from corresponding male. Values are mean ± 
SEM from 6-13 animals. 
 
 Striatum mPFC 
Wt 3013 ± 164 130 ± 20 
S-COMT deficient 2421 ± 241 140 ± 33 
Male 
COMT-KO 2627 ± 152 127 ± 7 
Wt 2344 ± 171+ 80 ± 6 
S-COMT deficient 2411 ± 126 127 ± 10* 
Female 
COMT-KO 2957 ± 175*# 144 ± 17** 
5.3  Western blotting and COMT protein distribution in S-COMT 
deficient mice (Study I) 
Next, the protein distribution and presence of COMT isoforms was studied by Western 
blot (Study I, Fig. 1C) and immunohistochemistry (Study I, Fig. 2). Western blot 
analysis from liver samples revealed the equal intensity of the longer MB-COMT (28 
kDa) and the shorter S-COMT (24 kDa) bands in Wt male mice. In females, the 
intensity of the MB-COMT band was slightly weaker than males. As expected, S-
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COMT deficient animals expressed only MB-COMT and similarly to Wt mice, the 
relative abundance of MB-COMT was lower in females than males. No COMT protein 
was detected in COMT-KO animals. 
With regards to immunolabelling of hepatic COMT, we found that the intensity of 
COMT staining in S-COMT deficient mice was notably lower than in Wt mice. 
Similar results were obtained in the duodenum, where COMT was abundantly 
expressed in the duodenal epithelial cells and microvilli of Wt animals, whereas S-
COMT deficient mice displayed lower immunostaining intensity. It should be noted 
that COMT staining in S-COMT deficient mice was seen only in intracellular 
membranes. As expected, no COMT immunoreactivity was detected in the duodenum 
or liver of the COMT-KO mice. 
5.4. Extracellular striatal, accumbal and prefrontal dopamine and 
 metabolite levels in S-COMT deficient mice after carbidopa/L-
dopa administration (Study II) 
Based on the findings that S-COMT deficiency decreases COMT activity in the brain, 
the next objective was to study the extracellular dopamine and metabolite 
concentrations in the CNS in these mice. Neither sex nor genotype had an effect on 
striatal dopamine levels after carbidopa/L-dopa (30/10 mg/kg, i.p.) administration. The 
dopamine levels in the NAcc on the other hand, were elevated more in S-COMT 
deficient animals than in Wt mice (p < 0.001; Study II, Fig. 4). However, no sex 
effects were found. Carbidopa/L-dopa increased prefrontal dopamine levels poorly in 
S-COMT deficient male mice, compared with male Wt mice, whereas the elevation in 
females was similar to that of Wt mice. 
The carbidopa/L-dopa induced DOPAC elevation was significantly higher in S-COMT 
deficient mice than in Wt mice both in the striatum and NAcc (Study II, Fig. 3 and 4). 
Also the increase in HVA levels in these brain areas was far less profound in the S-
COMT deficient mice than in Wt littermates. In the mPFC, the S-COMT deficient 
mice displayed a significant increase in DOPAC levels, but unlike to the other brain 
areas, no HVA reduction was seen (Study II, Fig. 5). 
5.5.  Extracellular striatal, accumbal and prefrontal dopamine and 
metabolite levels in COMT-KO mice after carbidopa/L-dopa 
 administration (unpublished) 
After this, we wanted to determine how the extracellular dopamine and metabolite 
levels in the striatum, NAcc and mPFC are affected by carbidopa/L-dopa (30/10 
mg/kg, i.p.) administration in both COMT-KO mice and their Wt littermates. 
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Figure 5.3. Extracellular dopamine (A/B), DOPAC (C/D) and HVA (E/F) concentrations in the 
striatum of COMT knockout (COMT-KO) and wild type (Wt) mice after administration of 
carbidopa/L-dopa (30/10 mg/kg, i.p.). The arrow indicates time-points of injections. CD = carbidopa, 
LD = L-dopa. Values are mean ± SEM from 8-15 animals. 
In general, dopamine levels were not affected by genotype in any of the brain regions 
studied (Fig. 5.3, 5.4 and 5.5A/B). However, significant sex differences were found 
both in the NAcc and in the mPFC. Females displayed higher dopamine concentrations 
than males in the NAcc (p < 0.05), whereas in the mPFC the increase was more 
pronounced in males than females (p < 0.001). Also, the relative increase in dopamine 
levels was more pronounced in the mPFC than in the two other brain areas studied. 
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Figure 5.4. Extracellular dopamine (A/B), DOPAC (C/D) and HVA (E/F) concentrations in the 
nucleus accumbens of COMT knockout (COMT-KO) and wild type (Wt) mice after administration of 
carbidopa/L-dopa (30/10 mg/kg, i.p.). The arrow indicates time-points of injections. CD = carbidopa, 
LD = L-dopa. Values are mean ± SEM from 8-15 animals. 
Carbidopa/L-dopa induced DOPAC levels were not influenced by sex, but they were 
significantly higher (p < 0.001) in COMT-KO mice than in Wt mice in all brain 
regions studied (Fig. 5.3, 5.4 and 5.5C/D).  HVA was increased in Wt mice as a result 
of carbidopa/L-dopa administration and, as expected, not detected in COMT-KO 
animals (Fig. 5.3, 5.4 and 5.5E/F). 
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Figure 5.5. Extracellular dopamine (A/B), DOPAC (C/D) and HVA (E/F) concentrations in the 
medial prefrontal cortex of COMT knockout (COMT-KO) and wild type (Wt) mice after administration 
of carbidopa/L-dopa (30/10 mg/kg, i.p.). The arrow indicates time-points of injections. CD = 
carbidopa, LD = L-dopa. Values are mean ± SEM from 8-15 animals. 
5.6. Baseline extracellular striatal, accumbal and prefrontal 
dopamine levels in COMT-KO mice (Study III) 
Next, we wanted to study how a lack of COMT affects the extracellular baseline levels 
of dopamine. The quantification, done by no-net-flux microdialysis, revealed that 
basal dopamine levels in the mPFC were significantly higher in COMT-KO mice than 
in Wt mice (p < 0.05; Fig. 5.6). Although females of both genotypes had slightly 
higher dopamine levels than males, no significance was found. The same effect was 
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not seen in the striatum or NAcc. In addition, the in vivo extraction fractions, reflecting 
the synaptic clearance of dopamine, remained unaltered in all brain areas (Study III, 
Table 1). 
 
Figure 5.6. Basal dopamine concentrations as indicated by point of no-net-flux in the medial 
prefrontal cortex of wild type (Wt) and COMT knockout (COMT-KO) mice. *P < 0.05 indicates a 
significant genotype effect between Wt and COMT-KO animals. Values are mean ± SEM from 6-8 
animals. 
5.7. Presence of DAT and NET in the striatum and prefrontal 
cortex of COMT-KO mice (Study III) 
Previous reports have shown that DAT is the dominant transporter in the striatum, 
whereas NET predominates in the prefrontal cortex (Javitch et al., 1984; Scatton et al., 
1985; Sesack et al., 1998). The same pattern of expression was confirmed in our 
immunohistochemistry studies in COMT-KO mice and their Wt littermates (Study III, 
Fig. 2). Moreover, our results proved that there is no up-regulation of DAT or NET in 
either brain region due to the lack of COMT. 
5.8. Extracellular striatal, accumbal and prefrontal dopamine and 
metabolite levels in COMT-KO mice after DAT, NET and MAO 
inhibition (Study III) 
DAT inhibition by GBR 12909 (20 mg/kg, i.p.) did not alter basal prefrontal dopamine 
levels in either COMT-KO or Wt mice (Fig 5.7). Nor did GBR 12909 change DOPAC 
or HVA levels in either sex (Study III, Fig. 4). Instead, after both NET (reboxetine, 20 
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mg/kg, i.p.) and non-selective MAO (pargyline, 100 mg/kg, i.p.) inhibition, the 
dopamine concentrations were elevated several fold in the mPFC of Wt mice (Fig. 
5.7). Additional COMT disruption nearly doubled the elevation in dopamine levels. 
With regards to DOPAC, the inhibition of NET did not further modify concentrations 
in either genotype and the levels remained higher in COMT-KO mice than in their Wt 
littermates throughout the experiment (Study III, Fig. 5). As expected, MAO inhibition 
on the other hand effectively decreased DOPAC levels in both genotypes and sexes 
(Study III, Fig. 6). HVA levels in Wt mice followed the changes of corresponding 
DOPAC levels, whereas in COMT-KO mice, no HVA was detected. 
Figure 5.7. The area under the concentration curve (AUC) values for dopamine in the medial 
prefrontal cortex (mPFC) after inhibition of DAT (GBR 12909, 20 mg/kg, i.p.), MAO (pargyline, 100 
mg/kg, i.p.) and NET (reboxetine, 20 mg/kg, i.p.) in both wild type (Wt) and COMT knockout (COMT-
KO) mice. Values are mean ± SEM from 6-9 animals. 
5.9. Striatal and accumbal extracellular dopamine and metabolite 
levels after tolcapone and THC administration (Study IV) 
Finally, we studied the effects of separate and combined tolcapone (30 mg/kg) and 
THC (3 mg/kg) on striatal and accumbal extracellular dopamine levels in Wt mice. No 
effects on extracellular dopamine levels were seen after single tolcapone (30 mg/kg) or 
THC (3 mg/kg) dosing. On the other hand, combined tolcapone and THC 
administration on the other hand increased accumbal (Fig. 5.8B; p < 0.05), but not 
striatal (Fig. 5.8A) dopamine levels compared to the other treatment groups. As 
expected, extracellular DOPAC levels were increased (Fig. 5.8C/D; p < 0.001) and 
HVA levels were decreased (Fig. 5.8E/F; p < 0.001) as a result of COMT inhibition by 
tolcapone. However, there was no evidence that this effect was modulated by 
subsequent THC, or that THC alone had any effects on DOPAC and HVA levels. 
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Figure 5.8. Separate and interactive effects of tolcapone (30 mg/kg) and THC (3 mg/kg) on dopamine, 
DOPAC and HVA in the dorsal striatum and nucleus accumbens (NAcc). First arrow indicates 
tolcapone/vehicle administration and the second arrow indicates THC/vehicle administration. 
Statistical analyses compared the three samples prior to tolcapone or THC administration (Pre-
Tol/Pre-THC) with the three samples following tolcapone or THC administration (Post-Tol/Post-
THC). *P < 0.05, due to a significant increase between pre-drug and post-drug time points in the 
Tol/THC group only.   ###P < 0.001, due to a significant change between pre-drug and post-drug time 
points in both tolcapone treated groups. Values are mean ± SEM from 6-12 animals. 
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6   DISCUSSION 
6.1 Distinguishing the role of COMT isoforms in general – Impact 
on enzyme activity and pharmacokinetics of oral L-dopa 
Earlier studies have suggested that S-COMT is the dominant polypeptide in peripheral 
tissues, whereas MB-COMT prevails in the brain, particularly in humans (Männistö 
and Kaakkola, 1999; Tenhunen et al., 1994). It has also been shown, that MB-COMT 
has higher affinity for catecholamines, especially at low physiological concentrations 
(Männistö and Kaakkola, 1999; Reenilä and Männistö, 2001). As for enzyme activity, 
S-COMT has been indicated as a high-capacity enzyme metabolizing high substrate 
concentrations with up to 30-fold higher activity than MB-COMT (Ellingson et al., 
1999; Lotta et al., 1995; Masuda et al., 2003). Our study revealed however, that the 
role of MB-COMT in L-dopa metabolism in the mouse is far greater than previously 
anticipated. 
The lack of S-COMT lowered COMT activity in the liver by approximately 50 and 70 
% in males and females, respectively, leaving MB-COMT to account for up to 50 % of 
total activity. In contrast to the liver, the total COMT activity in the duodenum was 
reduced relatively more in males than in females. Both hepatic and duodenal COMT 
activities were lower in Wt females than Wt males, presumably reflecting the reported 
estrogen induced down-regulation of COMT (Xie et al., 1999). In the brain, the striatal 
and prefrontal COMT activity in S-COMT deficient mice was reduced in a similar 
manner (60-70 %) as seen in the peripheral tissues. Interestingly and similarly to the 
discoveries in heterozygous COMT-KO mice (Huotari et al., 2002a), the sex related 
differences in COMT activity evident in the peripheral tissues, were not seen in the 
brain of either genotype. With regards to compensatory mechanisms, although a lack 
of S-COMT could theoretically result in enhanced expression of MB-COMT and 
thereby leading to an overestimation in its role, no evidence of such up-regulation was 
seen in our Western blot analyses of S-COMT deficient animals. 
After oral L-dopa administration, we found that L-dopa concentrations in COMT-KO 
mice were doubled in the plasma and liver compared to Wt mice. In addition, visual 
inspection of L-dopa levels also revealed a slightly prolonged elimination time in 
plasma of male COMT-KO mice. The L-dopa increase seen in S-COMT deficient 
mice was about one half of the increase seen in COMT-KO mice, reflecting the 
activity results on the role of MB-COMT. In the duodenum, a similar increasing effect 
of COMT deficiency on L-dopa levels was seen in male mice, whereas in females, a 
lack of COMT did not increase L-dopa concentrations. These sex-dependent results 
are in concordance with our activity studies, where total duodenal COMT activity in 
S-COMT deficient mice was decreased relatively more in males than females. They 
also indicate the accentuated role of COMT in peripheral L-dopa metabolism in males. 
In all peripheral tissues, the levels of 3-OMD, an L-dopa metabolite, were decreased in 
S-COMT deficient animals by about one half from the levels measured in Wt mice. 
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Females tended to have slightly lower 3-OMD levels than males in both Wt and S-
COMT deficient mice. 
In the brain, both striatal and prefrontal L-dopa levels were unaffected by sex and 
genotype. 3-OMD levels in the brain behaved similarly to those of the peripheral 
tissues, with highest levels found in male Wt mice as expected. These results were 
consistent with previous assessments done after intraperitoneal administration in 
COMT-KO mice (Huotari et al., 2002a). With regards to tissue dopamine levels, an 
elevation in the PFC and hypothalamus, but not in the striatum, was seen previously in 
both sexes of COMT-KO mice (Huotari et al., 2002a). In our study, however, 
dopamine levels in males were unaffected by area and genotype, whereas dopamine 
levels in females were elevated both in the striatum and mPFC as a function of COMT 
deficiency. The differences between the studies may be a reflection of the different 
dosing regimens. Allegedly, the bioavailability of parenteral L-dopa is higher than that 
of oral L-dopa (Kääriäinen et al., in press). 
Collectively, these results demonstrate that MB-COMT can partially compensate for 
the absence of S-COMT, and indicate that in peripheral L-dopa metabolism in mice, 
the role of MB-COMT is more pronounced than previously anticipated. The 
differences in peripheral COMT activity between this study and the previous one, 
could be explained by the difficulties of in vitro biochemical separation of the two 
isoforms, often leading to an overestimation of S-COMT as also admitted by Ellingson 
et al. (1999). Furthermore, as duodenal L-dopa concentrations and plasma elimination 
times were increased only in males, and as brain dopamine elevation was conversely 
seen only in females, the present study suggests that the importance of COMT in L-
dopa pharmacokinetics is dependent of sex and tissue.  
6.2 Distinguishing the roles of COMT isoforms in the brain – 
Impact on extracellular dopamine levels in the striatum, 
nucleus accumbens and mPFC 
Previous studies have failed to show differences in striatal or hypothalamic tissue 
dopamine concentrations under normal conditions between COMT-KO mice and their 
Wt littermates (Gogos et al., 1998; Huotari et al., 2002a). At the same time, results 
from tissue studies in the PFC have been conflicting. Although not statistically 
significant, a two-three-fold increase in prefrontal dopamine was seen in male COMT-
KO mice compared to their Wt littermates (Gogos et al., 1998), a result that could not 
later be replicated by Huotari et al (2002). The deviation in results might be explained 
by differences in dissection. The dissected area in the study by Gogos et al. (1998) 
included mainly areas from the mPFC, whereas in the study by Huotari et al. (2002), 
other cortical areas such as the motor cortices were included as well. Furthermore, no 
effects on striatal or accumbal extracellular and tissue dopamine levels or dopamine 
outflow, has been measured after treatment with either tolcapone or entacapone in rats 
(Acquas et al., 1992; Brannan et al., 1992; Huotari et al., 1999; Kaakkola and 
Wurtman, 1992; Kaakkola and Wurtman, 1993; Li et al., 1998; Maj et al., 1990; 
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Napolitano et al., 2003; Raevskii et al., 2002). Our findings, indicating that COMT 
deficiency does not induce changes in striatal and accumbal extracellular dopamine 
levels under basal conditions, are in agreement with these and previous findings from 
another microdialysis study in COMT-KO mice (Huotari et al., 2004). However, in 
difference to previous results, showing no increases in basal extracellular prefrontal 
dopamine after tolcapone treatment in rats (Tunbridge et al., 2004), our no-net-flux 
study unequivocally demonstrates that the extracellular dopamine levels are 
significantly elevated in the mPFC of mice lacking COMT. It is noteworthy that such 
an increase in dopamine levels could not be detected previously by conventional 
microdialysis, and that the difference in studies might be related to the species or 
methods used. Technical reasons are of importance, as the no-net-flux method can be 
kept more reliable and sensitive than conventional microdialysis sampling with a low 
recovery. It has to also be noted that although tolcapone failed to increase basal 
dopamine concentrations, it did elevate the clozapine and high potassium-induced 
prefrontal dopamine efflux in the same study. 
After an L-dopa challenge, the only significant genotype effect on dopamine levels 
was seen in the NAcc, where S-COMT deficient mice had higher concentrations than 
their Wt littermates. Male COMT-KO mice displayed higher dopamine levels in the 
mPFC than females, whereas dopamine levels in the NAcc behaved in an opposite 
way. Previous microdialysis and tissue studies in rats have shown that both tolcapone 
(Acquas et al., 1992; Brannan et al., 1992; Huotari et al., 1999; Kaakkola and 
Wurtman, 1993; Männistö et al., 1992a; Raevskii et al., 2002) and entacapone 
(Kaakkola and Wurtman, 1993; Männistö et al., 1992a), used in conjunction with L-
dopa, elevate dopamine levels in the striatum and hypothalamus. In COMT-KO mice 
on the other hand, a dose of L-dopa did not elevate tissue dopamine levels in the 
striatum, but cortical levels were increased in both sexes (Huotari et al., 2002a). One 
explanation for the discrepancies is that the dose of L-dopa used in our study may have 
been too low to highlight the effects of Comt gene disruption on extracellular 
dopamine. In addition, the presence of yet unidentified compensatory mechanisms in 
COMT-KO mice could also have affected our results. However, MAO activity and 
MAO protein levels remain unaltered in the brain and kidneys of COMT-KO animals 
as described by Huotari et al. (2002) and Odlind et al. (2002). Similarly, DAT levels 
and function appear to be unaltered in these mice (Huotari et al., 2002b; Yavich et al., 
2007). Additionally, in section 5.7 we show that Comt gene disruption does not appear 
to have an effect on NET and DAT immunoreactivity. 
DOPAC levels were accumulated after L-dopa administration in both S-COMT and 
COMT-KO animals compared to Wt mice. In the striatum of S-COMT deficient mice, 
DOPAC levels were increased more in males than in corresponding females. This 
singular sex effect might simply be due to already elevated basal DOPAC levels, as 
the relative increase from mean basal values to Cmax was of a similar magnitude in both 
males and females (up by 119 % and 140 %, respectively). These results are in line 
with studies done in COMT-KO mice and after pharmacological COMT inhibition 
(Huotari et al., 2002a; Kaakkola and Wurtman, 1993; Napolitano et al., 2003). 
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As expected, no HVA was seen in COMT-KO animals. In the S-COMT deficient 
mice, extracellular HVA levels were decreased both in the striatum and NAcc, but 
surprisingly not in the mPFC. As DOPAC to HVA conversion, especially in the mPFC 
of female mice was not reduced by the absence of S-COMT, the results may indicate a 
brain area and sex-specific role for COMT isoforms. These results are also supported 
by experiments done in Study I, where tissue HVA levels were elevated equally in 
female S-COMT deficient animals and their Wt littermates after oral L-dopa 
treatment. With regards to protein abundance, previous studies done in males have 
shown a similar expression pattern of both COMT isoforms in the PFC (Hill et al., 
2007; Myöhänen et al., 2010). Unfortunately these studies have not been replicated in 
females. 
The enzyme activity and neurochemical changes in S-COMT deficient mice were 
accompanied by some interesting behavioural phenotypes compared to Wt littermates: 
S-COMT deficient mice displayed an increased acoustic startle response testing the 
ability to hear and respond to aversive stimulus in a protective manner. A similar 
increase has been shown also in COMT-KO mice (Papaleo et al. 2008) and even in 
humans with low COMT protein expression and enzyme activity (Roussos et al., 
2009). As changes in prefrontal COMT activity have been suggested to affect 
midbrain dopamine biosynthesis (see section 2.5) and as the VTA is closely involved 
in the pathway regulating acoustic startle response (Koch, 1999), the enhancement of 
acoustic startle in Comt disrupted mice is probably indirectly related to total (COMT-
KO) or partial (S-COMT deficiency) disruption of prefrontal COMT activity. In 
addition to changes in acoustic startle, the S-COMT deficient mice exhibited also non-
aggressive social dominance as well as increased sniffing behaviour and barbering of 
whiskers compared to Wt littermates. These subtle changes in social interaction might 
indicate that S-COMT deficient mice are more insistent and therefore gain social 
dominance over Wt mice. The barbering of whiskers might be a result of harmful 
social interactions or, as aggressiveness was normal in these mice, more likely an 
indicator of stress (Kalueff et al., 2006). 
Conclusively, these results provide evidence for a crucial and specific role of COMT 
in dopamine metabolism in the mPFC that is also reflected in behavioural phenotypes. 
They also shed light on why stimulus-evoked dopamine release is higher and 
dopamine clearance is longer in COMT-KO mice than in the Wt mice (Yavich et al., 
2007).  Furthermore, it seems that S-COMT has a brain area and also sex-dependent 
role in dopamine metabolism. Especially in the PFC, MB-COMT seems to be able to 
compensate for the lack of S-COMT to a large extent. 
6.3 Role of COMT, DAT, NET and MAO on prefrontal dopamine 
metabolism in mice 
We were able to determine the relative contribution of DAT, NET and MAO in 
prefrontal dopamine clearance of both COMT-KO and Wt mice using their respective 
pharmacological inhibitors. DAT inhibition did not alter dopamine levels in either 
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genotype, whereas both NET and MAO inhibition elevated dopamine concentrations 
several-fold in Wt mice. This effect was generally doubled as a result of COMT 
deficiency, indicating that about half of the dopamine clearance in the mPFC of mice 
occurs through NET uptake and subsequent MAO catabolism, and the remaining half 
through COMT. Such a comprehensive quantification has not been done before and 
various mechanisms have been quantified very seldom. As mentioned before, one 
quantification with similar results regarding the role of COMT was done by Karoum et 
al. (1994), who concluded that 3-MT represented approximately 60 % of prefrontal 
and less than 15 % of striatal dopamine metabolites in rats. Our results are also in line 
with previous microdialysis studies reporting important roles for both NET (Di Chiara 
et al., 1992; Moron et al., 2002; Tanda et al., 1994; Yamamoto and Novotney, 1998) 
and MAO (Wayment et al., 2001) in the regulation of prefrontal dopaminergic 
neurotransmission in rats. DAT on the other hand, has also previously been seen as a 
minor player, as inhibition of this transporter demonstrates only weak dopamine 
elevating effects in the mPFC of rats (Cass and Gerhardt, 1995). 
Both DOPAC and HVA levels were unaffected by inhibition of DAT and NET in both 
genotypes and sexes. Extracellular DOPAC concentrations in COMT-KO mice were, 
however, many times higher than those recorded in their Wt littermates. The fact that 
NET inhibition did not decrease DOPAC levels indicates that the majority of 
dopamine metabolism occurs in the same cell where it is synthesized. This was also 
proposed by Eisenhofer et al. (2004), who concluded that only a small fraction of 
catecholamine metabolites is formed from released catecholamines. In contrast to the 
findings of Wayment et al. (2001), our results show that MAO inhibition by pargyline 
effectively decreases prefrontal extracellular DOPAC levels in both genotypes and 
sexes. The difference in DOPAC levels after pargyline administration may be 
explained by different dosing regimens. In our study, pargyline was given 
systemically, whereas Wayment et al. (2001) used local administration where the drug 
was dissolved in artificial CSF and given through the microdialysis probe. One 
disadvantage of this local administering technique is that the drug must diffuse 
through the probe membrane before it reaches the surrounding tissue. The exact dose 
is thereby uncertain and dependent on the experimental set-up and features of the 
probe (i.e. flow rate, probe cut-off etc.). 
In conclusion, by inhibiting transporter and MAO activities, we provide strong 
evidence that in the mPFC, sequential NET and MAO action accounts for 
approximately 50% of dopamine elimination, whereas sequential uptake2 and COMT 
eliminates the remaining 50% of the neurotransmitter. DAT on the other hand plays a 
minor, if any, role in the clearance of cortical dopamine. These results corroborate our 
no-net-flux results described in Section 5.6, and when taken together, indicate that 
COMT indeed is one of the key players in prefrontal dopamine metabolism. 
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6.4 Effects of simultaneous COMT inhibition and THC on 
 extracellular dopamine levels in the stratum and nucleus 
 accumbens 
Cannabis and particularly its psychoactive component THC have been suggested to 
worsen already existing psychotic symptoms or, together with other factors, induce 
psychotic disorders (Sewell et al., 2009). Neurochemically, THC acting via the 
cannabinoid receptor type 1 (CB1), has been shown to increase the dopaminergic 
neurotransmission in the rat NAcc shell but not in the NAcc core (Tanda et al., 1997). 
Also prefrontal extracellular dopamine and glutamate levels have been reported to 
increase in THC treated rats (Pistis et al., 2002). Therefore, as both COMT (see 
section 2.5) and cannabis have been implicated in the dopaminergic function of the 
mesocortical pathways, and as dysregulation of the complex array of these pathways 
likely reflects the onset of adulthood psychosis (Moore et al., 1999), the gene x 
environment interaction studies between these two factors have gained moderate 
interest recently.  
Indeed, the Val/Met polymorphism has been implicated in the susceptibility of adult 
onset psychosis in adolescent cannabis users (Caspi et al., 2005). This group reported a 
strong gene x environment interaction between COMT and cannabis use at ages below 
15, in relation to the prevalence of adulthood psychotic symptoms. Conclusively, Val 
homozygous cannabis users were associated with a higher risk for adult onset of 
psychotic symptoms and the progression of schizophreniform disorder than Met 
homozygotes. The Val allele has also been associated with an earlier onset of 
psychotic symptoms in cannabis users (Estrada et al., 2011), a higher susceptibility to 
cannabis dependence (Baransel Isir et al., 2008), sensitivity to THC induced memory 
and attention impairments as well as sensitivity to THC induced psychosis and 
hallucinations in persons with pre-existing psychosis liability (Henquet et al., 2006; 
Henquet et al., 2009). Because the high activity Val allele has been linked to an 
increased risk for psychosis consequent to THC intake in humans, one might expect to 
see an improvement in behavioural phenotypes related to psychosis in THC treated 
COMT-KO mice. Paradoxically however, THC treatment during adolescence induced 
a larger increase in several psychosis-related behavioural phenotypes in adult COMT-
KO mice than in their Wt littermates (O'Tuathaigh et al., 2010). Hyperactivity in the 
mesolimbic dopamine system has previously been linked to positive symptoms in 
schizophrenia (Kuepper et al., 2010) and therefore our results, showing that COMT 
inhibition elevates THC induced dopamine release in the NAcc, complements the 
study O'Tuathaigh et al. (2010). The fact that both a low and no (tolcapone and 
COMT-KO) as well as a high (Val allele) COMT activity induces psychotic 
characteristics, corroborates the building evidence of the inverted U-shaped 
relationship between prefrontal dopaminergic activity and cognitive function in the 
PFC (Fig. 6.1) (Goldman-Rakic et al., 2000; Tunbridge et al., 2006). 
The findings from microdialysis studies investigating the effects of THC on accumbal 
dopamine have been mixed. Our results show inconsistency with those discovered by 
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Figure 6.1. The inverted U-shaped association between dopamine signalling and the prefrontal cortex 
function. 
Robledo et al. (2007) and by Chen et al. (1990), both showing that single THC 
administration increases accumbal extracellular dopamine in mice and rats, 
respectively. However, both the mouse strain and THC dose (0.3-1.0 mg/kg) in these 
studies differed from our experiments. The discrepancies between the results might 
therefore indicate strain-specific genetic factors affecting the individual response to 
THC in mice. In fact, strain-specific effects of THC on accumbal dopamine have 
previously been demonstrated in rats (Chen et al., 1991). On the other hand, no effects 
of THC on accumbal dopamine were seen in another microdialysis study using higher 
(up to 10 mg/kg) doses (Castaneda et al., 1991). The fact that lower (< 3 mg/kg) THC 
doses generally seem to elevate accumbal dopamine, whilst higher do not, might 
indicate a bell-shaped dose-response curve for THC seen previously in locomotor 
activity experiments (Sanudo-Pena et al., 2000).  
Conclusively, the fact that THC elevates mesolimbic dopamine after COMT inhibition 
provides neurochemical evidence for a gene x environment interaction. Together with 
previously obtained results, our experiments indicate that dysregulation of prefrontal 
dopaminergic activity either through a high or low COMT activity predisposes to the 
psychosis inducing effects of THC. In addition, the dose-response for THC might not 
be linear and effects on dopamine turnover could be affected by strain. 
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7   CONCLUSIONS 
The present studies were done to elucidate the importance of COMT in prefrontal 
dopamine metabolism and to distinguish the roles of two different COMT isoforms 
using COMT knockout and S-COMT deficient mice as tools. The major findings and 
conclusions are as follows: 
I MB-COMT is accountable for about 30-50 % of total COMT activity in 
all tissues indicating that its proportional role is greater than previously 
anticipated. This is reflected also in the altered pharmacokinetics of 
exogenous L-dopa in S-COMT deficient mice. 
II A complete lack of COMT affected duodenal L-dopa levels only in 
males, whereas prefrontal dopamine concentrations were affected only 
in females following oral L-dopa administration. These results indicate 
that COMT modulates dopamine transmission in a tissue- and sex-
specific way. 
III NET and MAO eliminate about one half of released dopamine and the 
remaining half is cleared through sequential uptake2 and COMT (Fig. 
7.1). The role of DAT in prefrontal dopamine clearance is minor if any. 
These results indicate a particular role for COMT in prefrontal cortical 
dopamine metabolism compared to the striatum and NAcc. 
IV Subsequent tolcapone and THC administration elevates dopamine levels 
in the NAcc supporting the clinical evidence of a gene x environment 
interaction between COMT and cannabis. 
Figure 7.1. The dopaminergic synapse and the metabolism 
of dopamine (DA) in the prefrontal cortex (PFC). 
Conclusively, we found that uptake into presynaptic 
noradrenergic neurons by the noradrenaline transporter 
(NET) and a subsequent metabolism by monoamine 
oxidase (MAO) constitutes about one half of dopamine 
clearance in the PFC, whereas the remaining half is 
eliminated through uptake2 mechanisms with subsequent 
metabolism by catechol-O-methyltransferase (COMT). The 
importance of the dopamine transporter (DAT) is minor. 3-
MT, 3-methoxytyramine; DOPAC, 3,4-dihydroxy-
phenylacetic acid; HVA, homovanillic acid; VMAT2, 
vesicular monoamine transporter 2. 
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